<SEC-DOCUMENT>0001654954-21-006720.txt : 20210609
<SEC-HEADER>0001654954-21-006720.hdr.sgml : 20210609
<ACCEPTANCE-DATETIME>20210609160904
ACCESSION NUMBER:		0001654954-21-006720
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20210608
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210609
DATE AS OF CHANGE:		20210609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		211005227

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm-20211231.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Blueprint from Issuer Direct Corp.--><!--Copyright 2019 Issuer Direct Corporation--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:cvm="http://www.cel-sci.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:enum="http://xbrl.org/2014/extensible-enumerations" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
   <head><title>ISDR Blueprint iXBRL Document</title><meta content="text/html; charset=UTF-8" http-equiv="Content-Type" />

   </head>
<body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric id="id6xP9DaUQwCNkM" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityCentralIndexKey">0000725363</ix:nonNumeric>
<ix:nonNumeric id="id6xP9DaUQwCNkK" contextRef="From-2021-06-08to2021-06-08" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
</ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20211231.xsd"/></ix:references><ix:resources><i:context id="From-2021-06-08to2021-06-08">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000725363</i:identifier>
</i:entity>
<i:period>
<i:startDate>2021-06-08</i:startDate>
<i:endDate>2021-06-08</i:endDate>
</i:period>
</i:context>
</ix:resources></ix:header></div>

<div style="margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000;text-align: center">
<!--style header--><br />
<br /></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNITED STATES</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SECURITIES AND EXCHANGE COMMISSION</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
WASHINGTON, D.C. 20549</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM <ix:nonNumeric id="idec6a66480ee9494bb78b4fde1e2adb8c" contextRef="From-2021-06-08to2021-06-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">CURRENT
REPORT</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">Pursuant
to Section 13 or 15(d) of the</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">Securities
Exchange Act of 1934</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">Date of
Report (date of earliest event reported): <ix:nonNumeric id="id76fdf93504ce4e5e89846bab44519683" contextRef="From-2021-06-08to2021-06-08" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">June 8,
2021</ix:nonNumeric></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
<ix:nonNumeric id="id550887ae360d4871804844d34f0a5456" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityRegistrantName">CEL SCI
CORP</ix:nonNumeric></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(Exact
name of Registrant as specified in its charter)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div>
<table style="width: 100%; font-family: Times New Roman; font-size: 13px" cellspacing="0" cellpadding="0">

<tbody><tr>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="idf036194ab4d74c2780b1339a74ece17f" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">
Colorado</ix:nonNumeric></span></div>
</td>
<td style="vertical-align: middle; width: 34%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">
<ix:nonNumeric id="id602659a9c3ff4c479d1fb017745bebe2" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityFileNumber">001-11889</ix:nonNumeric></span></div>
</td>
<td style="vertical-align: middle; width: 34%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="idcc2be5cf16fd4c9aa2359de1dd73eeb1" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityTaxIdentificationNumber">
84-0916344</ix:nonNumeric></span></div>
</td>
</tr>
<tr>
<td style="vertical-align: middle; width: 33%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction of incorporation)</span></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(Commission
File No.)</span></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(IRS
Employer Identification No.)</span></div>
</td>
</tr>

</tbody></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="idc255ddcb33774a289764c5ed23496f54" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityAddressAddressLine1">
8229 Boone Blvd.</ix:nonNumeric>, <ix:nonNumeric id="id441b2f3a6e6e42d5a8037d7a2e40f499" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityAddressAddressLine2">#802</ix:nonNumeric></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
<ix:nonNumeric id="id1c36cc9261704e4db87c879fdbd0a59b" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityAddressCityOrTown">Vienna</ix:nonNumeric>,
<ix:nonNumeric id="idf665df6213a741d28d9ce378cd5b8a7c" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric>
<ix:nonNumeric id="id96f0665e12514009aea88d0a8ea2bc02" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityAddressPostalZipCode">22182</ix:nonNumeric></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices, including Zip Code)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">Registrant&#x2019;s
telephone number, including area code:&#xA0; <span style="text-decoration: underline">(<ix:nonNumeric id="id820ea57840c9474280a6a3e2c580088f" contextRef="From-2021-06-08to2021-06-08" name="dei:CityAreaCode">703</ix:nonNumeric>)
<ix:nonNumeric id="id569c86b4538f491eb6b8a1a822102835" contextRef="From-2021-06-08to2021-06-08" name="dei:LocalPhoneNumber">506-9460</ix:nonNumeric></span></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
N/A</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px">(Former
name or former address if changed since last report)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px"><span style="">
<ix:nonNumeric id="id29749334e81644a09d472b54db33804e" contextRef="From-2021-06-08to2021-06-08" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>&#xA0;Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px"><span style="">
<ix:nonNumeric id="idf6fea039f654405da59d8a266335231c" contextRef="From-2021-06-08to2021-06-08" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>&#xA0;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px"><span style="">
<ix:nonNumeric id="id797ee6e52ced4480982f566616f0f1f3" contextRef="From-2021-06-08to2021-06-08" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>&#xA0;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px"><span style="">
<ix:nonNumeric id="id3d77b48cf527403c82f7cebac8392029" contextRef="From-2021-06-08to2021-06-08" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>&#xA0;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-14c))</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Securities registered pursuant to Section 12(b) of the
Act:</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div>
<table style="width: 100%; font-family: Times New Roman; font-size: 13px" cellspacing="0" cellpadding="0">

<tbody><tr>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Title of Each Class</span></div>
</td>
<td style="vertical-align: middle; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Trading Symbol(s)</span></div>
</td>
<td style="vertical-align: middle; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="color: #231F20; font-family: Times New Roman; font-size: 13px">
Name of Each Exchange on Which Registered</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: middle; width: 33%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="ida591fd9dabe14e6680ad29dccb1e1835" contextRef="From-2021-06-08to2021-06-08" name="dei:Security12bTitle">
Common Stock</ix:nonNumeric></span></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="idbcfc16aaaf7142758160b9a0f0c4d688" contextRef="From-2021-06-08to2021-06-08" name="dei:TradingSymbol">
CVM</ix:nonNumeric></span></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-family: Times New Roman; font-size: 13px"><ix:nonNumeric id="id8433432dc6c34d05a0ad5bebc389e395" contextRef="From-2021-06-08to2021-06-08" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">
NYSE</ix:nonNumeric> American</span></div>
</td>
</tr>

</tbody></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;203.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;204.12b-2 of this chapter.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">Emerging
growth company <span style=""><ix:nonNumeric id="id9254cc13d2204843b6b7d740a7b7aa0d" contextRef="From-2021-06-08to2021-06-08" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <span style="">&#x2610;</span></span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000;text-align: center">
<!--style footer--><br />
<br /></div>

<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 1.01&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Entry into a Material
Definitive Agreement.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px"><span style="color: #000000">On June 8, 2021, CEL-SCI Corporation (the
&#x201C;Company&#x201D;) entered into an Underwriting Agreement with
Kingswood Capital Markets,</span> division of Benchmark
Investments, LLC <span style="color: #000000">as Representative of
the several underwriters, pursuant to which the Company agreed to
issue and sell 1,000,000 shares of common stock at a public
offering price of $22.62 per share. On June 8, 2021, the Company
entered into an Amended and Restated Underwrinting Agreement with
Kingswood Capital Markets, division of Benchmark Investments, LLC,
as representative of the underwriters identified therein, pursuant
to which the Company agreed to issue and sell 1,400,000 shares of
common stock at a public offering price of $22.62 per share. Under
the terms of the Amended and Restated Underwriting Agreement, the
Company granted the Underwriters a 30-day option to purchase up to
an additional 210,000 shares of common stock solely to cover
over-allotments. The Company expects to receive approximately $29.3
million in net proceeds from the Offering (excluding the
over-allotment option), after deducting underwriting discounts and
commissions and estimated offering expenses. The shares are being
offered and sold pursuant to the Company&#x2019;s effective
registration statement on Form S-3 (Registration No. 333-226558),
which was declared effective by the Securities Exchange Commission
(the &#x201C;SEC&#x201D;) on August 24, 2018, and the base prospectus
included therein, as amended and supplemented by the prospectus
supplement dated June 8, 2021. The Offering is expected to close on
or about June 11, 2021, subject to satisfaction of customary
closing conditions. The Company intends to use the net proceeds
from the Offering</span> to fund the continued development of
Multikine and LEAPS and for other general corporate
purposes<span style="color: #000000">.</span></span></div>
<div style="margin-left: 12px; margin-right: 5px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Amdneded and Restated Underwriting Agreement contains customary
representations, warranties and covenants of the Company, customary
conditions to closing, indemnification obligations of the Company
and the Underwriters, including for liabilities under the
Securities Act of 1933, as amended, and termination and other
provisions customary for transactions of this nature. The Company
has agreed to not sell any of its securities for a period of 30
days from June 8, 2021 subject to limited exceptions. All of the
Company&#x2019;s executive officers and directors have also agreed
not to sell or transfer any securities of the Company held by them
for a period of 30 days from June 8, 2021 subject to limited
exceptions.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">The
agreement of the Company not to sell any of its securities and the
agreements of the Company&#x27;s officers and directors not to sell or
transfer any of the Company&#x27;s securities for this 30 day period
will not apply after the Company publicly discloses the results of
its Phase III clinical trial.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">The
above description of the Amended and Restated Underwriting
Agreement is qualified in its entirety by the Amended and Restated
Underwriting Agreement which is attached to this report as Exhibit
1.1.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 12px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
8.01&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Other
Events.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">On
June 8, 2021, the Company issued a press release announcing that it
had priced the Offering, which press release is filed as Exhibit
99.1 to this report.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px;">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px;">On
June 8, 2021, the Company issued a press release announcing that it
had increased the size of the Offering to 1,400,000 shares, which
press release is filed as Exhibit 99.2 to this
report.<br /></span></div>
<div style="margin-left: 12px; margin-right: 5px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">This
Current Report on Form 8-K contains forward-looking statements that
are made pursuant to the safe harbor provisions within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements include, but are not limited to,
statements related to the anticipated closing of the Offering and
the amount of net proceeds expected from the Offering.
Forward-looking statements are based on management&#x2019;s current
expectations and are subject to risks and uncertainties, many of
which are beyond our control, which may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond the Company&#x2019;s
control, include the Company&#x2019;s ability to satisfy certain
conditions to closing on a timely basis or at all, as well as other
risks described in the section entitled &#x201C;Risk Factors&#x201D;
and elsewhere in the Company&#x2019;s Annual Report on Form 10-K
filed with the SEC on December 29, 2020 and in the Company&#x2019;s
other filings with the SEC, including, without limitation, its
reports on Forms 8-K and 10-Q, all of which can be obtained on the
SEC website at www.sec.gov. Readers are cautioned not to place
undue reliance on the forward-looking statements, which speak only
as of the date on which they are made and reflect
management&#x2019;s current estimates, projections, expectations and
beliefs. The Company expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>

<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Item&#xA0;9.01 Financial Statements and Exhibits.</span></div>
<div style="margin-left: 96px; margin-right: 0px; text-indent: -96px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div>
<table style="width: 100%; font-family: Times New Roman; font-size: 13px" cellspacing="0" cellpadding="0">

<tbody><tr>
<td style="vertical-align: middle; width: 9%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Exhibit&#xA0;No.</span></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Description</span></div>
</td>
</tr>
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left"><a href="celsci_ex11.htm"><span style="font-family: Times New Roman; font-size: 13px;">1.1</span></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Amended
and Restated Underwriting Agreement dated as of June 8, 2021, by
and between CEL-SCI Corporation and Kingswood Capital Markets,
division of Benchmark Investments, LLC, as a Representative of the
Several Underwriters</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: middle; width: 9%;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left"><a href="celsci_ex5.htm"><span style="font-family: Times New Roman; font-size: 13px;">5</span></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Opinion
of Hart &amp; Hart, LLC</span></div>
</td>
</tr>
<tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 9%;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left"><a href="celsci_ex23.htm"><span style="font-family: Times New Roman; font-size: 13px;">23</span></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Consent
of Hart &amp; Hart, LLC</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: middle; width: 9%;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left"><a href="celsci_ex991.htm"><span style="font-family: Times New Roman; font-size: 13px;">99.1</span></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Press
Release dated June 8, 2021</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: middle; width: 9%;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left"><a href="celsci_ex992.htm"><span style="font-family: Times New Roman; font-size: 13px;">99.2</span></a></div>
</td>
<td style="vertical-align: middle; width: 1%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: middle; width: 90%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Press
Release dated June 8, 2021<br /></span></div>
</td>
</tr>

</tbody></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>

<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
&#xA0;</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: center">
<span style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div>
<table style="width: 100%; font-family: Times New Roman; font-size: 13px" cellspacing="0" cellpadding="0">

<tbody><tr>
<td style="vertical-align: top; width: 49%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: bottom; width: 39%" colspan="2">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px"><span style="font-weight: bold">
CEL-SCI CORPORATION</span>&#xA0;&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: top; width: 49%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 36%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: top; width: 49%; border-bottom: 4px double #ffffff">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Date:
<span style="color: #000000">June 9, 2021</span></span></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: 4px double #ffffff">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">By:&#xA0;&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 36%; border-bottom: 2px solid #000000">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">/s/
Geert Kersten</span></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #ffffff">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: top; width: 49%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: bottom; width: 36%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</span></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
</tr>
<tr>
<td style="vertical-align: top; width: 49%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 36%">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: left">
<span style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer&#xA0;</span></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
</td>
</tr>

</tbody></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 48px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;text-align: justify">
<span style="font-family: Times New Roman; font-size: 13px">&#xA0;</span></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>celsci_ex11.htm
<DESCRIPTION>UNDERWRITING AGREEMENT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>celsci_ex11</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Exhibit 1.1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AMENDED and RESTATED</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
UNDERWRITING AGREEMENT</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
between</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI Corporation</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
and</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments,
LLC</font><font style="color: #000000">,</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
as Representative of the Several Underwriters</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNDERWRITING AGREEMENT</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
New York, New York</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
June 8, 2021</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments,
LLC</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">As Representative of the several Underwriters
named on</font> <font style="text-decoration: underline; color: #000000">Schedule 1</font>
<font style="color: #000000">attached hereto</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">590 Madison Avenue, 39</font><font style="font-size: 70%; vertical-align: top; color: #000000">th</font>
<font style="color: #000000">Floor</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">New
York, New York 10022</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Ladies
and Gentlemen:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
undersigned, CEL-SCI Corporation, a corporation formed under the
laws of the State of Colorado (collectively with its subsidiaries
and affiliates, including, without limitation, all entities
disclosed or described in the Registration Statement (as
hereinafter defined) as being subsidiaries or affiliates of CEL-SCI
Corporation the &#x201C;Company&#x201D;), hereby confirms its amended
and restated underwriting agreement (this &#x201C;Agreement&#x201D;),
which amends and restates the underwriting agreement previously
entered into for 1,000,000 shares of the Company's common stock,
par value $0.01 per share, with Kingswood Capital Markets, division
of Benchmark Investments, LLC (hereinafter referred to as
&#x201C;you&#x201D; (including its correlatives) or the
&#x201C;Representative&#x201D;) and with the other underwriters named
on Schedule 1 hereto for which the Representative is acting as
representative (the Representative and such other underwriters
being collectively called the &#x201C;Underwriters&#x201D; or,
individually, an &#x201C;Underwriter&#x201D;) on the terms and
conditions set forth herein.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">1.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PURCHASE
AND SALE OF SECURITIES.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">1.1
Firm Shares.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">1.1.1
Nature and Purchase of Firm Shares.</font> <font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(i)&#xA0; On the
basis of the representations and warranties herein contained, but
subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate
of 1,400,000, (the <font style="font-weight: bold">&#x201C;Firm
Shares&#x201D;)</font> of the Company's common stock, par value
$0.01 per share (the &#x201C;<font style="font-weight: bold">Common
Stock).</font></font></div>
<div style="margin-left: 84px; text-indent: 156px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(ii)&#xA0;
The Underwriters, severally and not jointly, agree to purchase from
the Company the number of Firm Shares set forth opposite their
respective names on Schedule 1 attached hereto and made a part
hereof at the purchase price of $21.0366 per Firm Share (93% of the
per Firm Share offering price) with respect to each Firm Share. The
Firm Shares are to be offered to the public at the offering price
set forth on the cover page of the Prospectus (as defined in
Section 2.1 hereof).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">1.1.2
Firm Shares Payment and Delivery.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(i)&#xA0; Delivery
and payment for the Firm Shares shall be made at 10:00 a.m.,
Eastern time, on the second (2nd) Business Day following the date
of this Agreement or at such earlier time as shall be agreed upon
by the Representative and the Company, at the offices of Nelson
Mullins Riley &amp; Scarborough LLP, 101 Constitution Avenue, NW,
Washington, DC 20001 (&#x201C;Representative Counsel&#x201D;), or at
such other place (or remotely by facsimile or other electronic
transmission) as shall be agreed upon by the Representative and the
Company. The hour and date of delivery and payment for the Firm
Shares is called the &#x201C;Closing Date<font style="font-weight: bold">.</font>&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; text-indent: 156px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">(ii)&#xA0; Payment
for the Firm Shares shall be made on the Closing Date by wire
transfer in Federal (same day) funds, payable to the order of the
Company upon delivery of the certificates (in form and substance
satisfactory to the Underwriters) representing the Firm Shares (or
through the facilities of the Depository Trust Company
(&#x201C;DTC&#x201D;)) for the account of the Underwriters. The Firm
Shares shall be registered in such name or names and in such
authorized denominations as the Representative may request in
writing at least two (2) full Business Days prior to the Closing
Date. The Company shall not be obligated to sell or deliver the
Firm Shares except upon tender of payment by the Representative for
all of the Firm Shares. The term &#x201C;Business Day&#x201D; means
any day other than a Saturday, a Sunday or a legal holiday or a day
on which banking institutions are authorized or obligated by law to
close in New York, New York.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="text-align: left; margin-left: 24px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">1.2
&#xA0; Over-allotment Option.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">1.2.1&#xA0; Additional
Shares</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company hereby grants to the Representative an option (the
&#x201C;Over-allotment Option&#x201D;) to purchase up to an
additional 210,000 shares of Common Stock, representing up to 15%
of the Firm Shares sold in the Offering (the &#x201C;Additional
Shares&#x201D;) for the purpose of covering over-allotments of such
securities, if any. The Firm Shares and the Additional Shares are
collectively referred to as the &#x201C;Securities.&#x201D; The
Securities shall be issued directly by the Company and shall have
the rights and privileges described in the Registration Statement,
the Disclosure Package and the Prospectus referred to below. The
offering and sale of the Securities is herein referred to as the
&#x201C;Offering<font style="font-weight: bold">.</font>&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">1.2.2&#xA0; Exercise of
Option</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Over-allotment Option granted pursuant to Section 1.2.1 hereof may
be exercised by the Representative as to all (at any time) or any
part (from time to time) of the Additional Shares within 30 days
after the date hereof. The purchase price to be paid per Additional
Share shall be equal to the price per Firm Share set forth in
Section 1.1.1(ii) hereof. The Representative shall not be under any
obligation to purchase any Additional Shares prior to the exercise
of the Over-allotment Option. The Over-allotment Option granted
hereby may be exercised by the giving of oral notice to the Company
from the Representative, which shall be confirmed in writing by
overnight mail or facsimile or other electronic transmission,
setting forth the number of Additional Shares to be purchased and
the date and time for delivery of and payment for the Additional
Shares (the &#x201C;<font style="font-weight: bold">Option Closing
Date</font>&#x201D;), which shall not be later than two (2) full
Business Days after the date of the notice or such other time as
shall be agreed upon by the Company and the Representative, at the
offices of Representative Counsel or at such other place (including
remotely by facsimile or other electronic transmission) as shall be
agreed upon by the Company and the Representative. If such delivery
and payment for the Additional Shares does not occur on the Closing
Date, the Option Closing Date will be as set forth in the notice.
Upon exercise of the Over-allotment Option with respect to all or
any portion of the Additional Shares, subject to the terms and
conditions set forth herein, the Company shall become obligated to
sell to the Representative, and the Representative shall purchase,
the number of Additional Shares specified in such
notice.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">1.2.3&#xA0; Payment and
Delivery</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Payment
for the Additional Shares shall be made on the Option Closing Date
by wire transfer in Federal (same day) funds, payable to the order
of the Company upon delivery to the Representative of certificates
(in form and substance satisfactory to the Representative)
representing the Additional Shares (or through the facilities of
DTC) for the account of the Representative. The Additional Shares
shall be registered in such name or names and in such authorized
denominations as the Representative may request in writing at least
one (1) full Business Day prior to the Option Closing Date. The
Company shall not be obligated to sell or deliver the Additional
Shares except upon tender of payment by the Representative for
applicable Additional Shares. The Option Closing Date may be
simultaneous with, but not earlier than, the Closing Date; and in
the event that such time and date are simultaneous with the Closing
Date, the term &#x201C;<font style="font-weight: bold">Closing
Date</font>&#x201D; shall refer to the time and date of delivery of
the Firm Shares and Additional Shares.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company represents and warrants to the Underwriters as of the
Applicable Time (as defined below), as of the Closing Date and as
of the Option Closing Date, if any, as follows::</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.1&#xA0;
Filing of Registration Statement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has filed with the U.S. Securities and Exchange Commission
(the &#x201C;<font style="font-weight: bold">Commission</font>&#x201D;) a registration
statement on Form S-3 (File No. 333-226558), including any related
prospectus or prospectuses, for the registration of the Securities
under the Securities Act of 1933, as amended (the
&#x201C;<font style="font-weight: bold">Securities
Act</font>&#x201D;), which registration statement was prepared by
the Company in all material respects in conformity with the
requirements of the Securities Act and the rules and regulations of
the Commission under the Securities Act (the &#x201C;<font style="font-weight: bold">Securities Act Regulations</font>&#x201D;) and
contains and will contain all material statements that are required
to be stated therein in accordance with the Securities Act and the
Securities Act Regulations. Except as the context may otherwise
require, such registration statement on file with the Commission at
any given time, including any amendments, exhibits and schedules
thereto at such time, documents filed as a part thereof or
incorporated pursuant to Item 12 of Form S-3 under the Securities
Act at such time and the documents and information otherwise deemed
to be a part thereof or included therein pursuant to Rule 430B of
the Securities Act Regulations (the &#x201C;<font style="font-weight: bold">Rule 430B Information</font>&#x201D;) or
otherwise pursuant to the Securities Act Regulations at such time,
is referred to herein as the &#x201C;<font style="font-weight: bold">Registration Statement</font>.&#x201D; The
Registration Statement at the time it originally became effective
is referred to herein as the &#x201C;<font style="font-weight: bold">Initial Registration Statement</font>.&#x201D;
If the Company files any registration statement pursuant to Rule
462(b) of the Securities Act Regulations, then after such filing,
the term &#x201C;<font style="font-weight: bold">Registration
Statement</font>&#x201D; shall include such registration statement
filed pursuant to Rule 462(b). The Registration Statement was
declared effective by the Commission on August 24,
2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">The
prospectus in the form in which it was filed with the Commission in
connection with the Initial Registration Statement is herein called
the <font style="font-weight: bold">&#x201C;Base
Prospectus.&#x201D;</font> Each preliminary prospectus supplement to
the Base Prospectus (including the Base Prospectus as so
supplemented) that described the Securities and the Offering and
omitted the Rule 430B Information and that was used prior to the
filing of the final prospectus supplement referred to in the
following paragraph is herein called a <font style="font-weight: bold">&#x201C;Preliminary
Prospectus.</font>&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">Promptly after the
execution and delivery of this Agreement, the Company will prepare
and file with the Commission a final prospectus supplement to the
Base Prospectus relating to the Securities and the Offering in
accordance with the provisions of Rule 430B and Rule 424(b) of the
Securities Act Regulations. Such final prospectus supplement
(including the Base Prospectus as so supplemented), in the form
filed with the Commission pursuant to Rule 424(b) under the
Securities Act is herein called the <font style="font-weight: bold">&#x201C;Prospectus.&#x201D;</font> Any reference
herein to the Base Prospectus, any Preliminary Prospectus or the
Prospectus shall be deemed to refer to and include the documents
incorporated by reference therein pursuant to Item 12 of Form S-3
under the Securities Act as of the date of such
prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Applicable Time</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>means 9:00 a.m., Eastern time, on
the date of this Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Disclosure Package</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>means any Issuer General Use Free
Writing Prospectus issued at or prior to the Applicable Time, the
Preliminary Prospectus dated June 8, 2021 and the information
included on Schedule 2-A hereto, all considered
together.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Issuer Free Writing
Prospectus</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>means any &#x201C;issuer free
writing prospectus,&#x201D; as defined in Rule 433 of the Securities
Act Regulations <font style="font-weight: bold">(&#x201C;Rule
433&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>including without limitation any
&#x201C;free writing prospectus&#x201D; (as defined in Rule 405 of
the Securities Act Regulations) relating to the Securities that is
(i) required to be filed with the Commission by the Company, (ii) a
&#x201C;road show that is a written communication&#x201D; within the
meaning of Rule 433(d)(8)(i), whether or not required to be filed
with the Commission, or (iii) exempt from filing with the
Commission pursuant to Rule 433(d)(5)(i) because it contains a
description of the Securities or of the Offering that does not
reflect the final terms, in each case in the form filed or required
to be filed with the Commission or, if not required to be filed, in
the form retained in the Company's records pursuant to Rule
433(g).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Issuer General Use Free Writing
Prospectus</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>means any Issuer Free Writing
Prospectus that is intended for general distribution to prospective
investors (other than a <font style="font-style: italic">&#x201C;bona fide</font> electronic road
show,&#x201D; as defined in Rule 433 (the <font style="font-weight: bold">&#x201C;Bona Fide Electronic Road
Show&#x201D;))</font>,<font style="font-weight: bold">&#xA0;</font>as evidenced by its being
specified in <font style="text-decoration: underline">Schedule
2-B</font> hereto.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Issuer Limited Use Free Writing
Prospectus</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>means any Issuer Free Writing
Prospectus that is not an Issuer General Use Free Writing
Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.2&#xA0;
Pursuant to the Exchange Act.</font> <font style="font-family: Times New Roman; font-size: 13px">The Common Stock is
registered pursuant to Section 12(b) of the Securities Exchange Act
of 1934, as amended (the <font style="font-weight: bold">&#x201C;Exchange Act&#x201D;).</font> The Company
has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange
Act, nor has the Company received any notification that the
Commission is contemplating terminating either such
registration.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.3&#xA0;
Stock Exchange Listing.</font> <font style="font-family: Times New Roman; font-size: 13px">The Common Stock is
listed on the NYSE American LLC (the <font style="font-weight: bold">&#x201C;NYSE
American&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>and
the Company has taken no action designed to, or likely to have the
effect of delisting the Common Stock from the NYSE American, nor
has the Company received any notification that the NYSE American is
contemplating terminating such listing, except as described in the
Registration Statement, the Disclosure Package and the
Prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">2.4&#xA0; No Stop Orders</font>, <font style="font-weight: bold">etc.</font></font> <font style="font-family: Times New Roman; font-size: 13px">Neither the
Commission nor, to the Company's knowledge, any state regulatory
authority has issued any order preventing or suspending the use of
the Registration Statement, any Preliminary Prospectus or the
Prospectus or has instituted or, to the Company's knowledge,
threatened to institute, any proceedings with respect to such an
order. The Company has complied with each request (if any) from the
Commission for additional information<font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.5&#xA0;
Disclosures in Registration Statement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; text-indent: 0px; margin-right: 0px;"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">2.5.1&#xA0;
Compliance with Securities Act and 10b-5
Representation.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(i)&#xA0; Each of
the Registration Statement and any post-effective amendment
thereto, at the time it became effective (including each deemed
effective date with respect to the Underwriters pursuant to Rule
430B or otherwise under the Securities Act) complied and will
comply in all material respects with the requirements of the
Securities Act and the Securities Act Regulations. The Company was
at the time of the filing of the Registration Statement eligible to
use Form S-3. The Company is currently eligible to use Form S-3
under the Securities Act and it meets the transaction requirements
for use of Form S-3 (including if applicable General Instruction
I.B.6 of Form S-3). Each Preliminary Prospectus and the Prospectus,
at the time each was or will be filed with the Commission, complied
and will comply in all material respects with the requirements of
the Securities Act and the Securities Act Regulations. Each
Preliminary Prospectus delivered to the Underwriters for use in
connection with this Offering and the Prospectus was or will be
identical to the electronically transmitted copies thereof filed
with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(ii)&#xA0; Neither
the Registration Statement nor any amendment thereto, at its
effective time, as of the Applicable Time, at the Closing Date or
at any Option Closing Date (if any), contained, contains or will
contain an untrue statement of a material fact or omitted, omits or
will omit to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the
circumstances under which they were made not
misleading.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(iii)&#xA0; The
Disclosure Package, as of the Applicable Time, at the Closing Date
or at any Option Closing Date (if any), did not, does not and will
not include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not
misleading; and each Issuer Limited Use Free Writing Prospectus
hereto does not conflict with the information contained in the
Registration Statement, the Preliminary Prospectus or the
Prospectus, and each such Issuer Limited Use Free Writing
Prospectus, as supplemented by and taken together with the
Preliminary Prospectus as of the Applicable Time, did not include
an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not
misleading; provided, however, that this representation and
warranty shall not apply to statements made or statements omitted
in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the
Representative expressly for use in the Registration Statement, the
Disclosure Package or the Prospectus or any amendment thereof or
supplement thereto. The parties acknowledge and agree that such
information provided by or on behalf of any Underwriter consists
solely of the following disclosure contained in the
&#x201C;Underwriting&#x201D; section of the Prospectus: ((a) the
fourth and fifth paragraphs, (b) the information set forth under
the sub-captions &#x201C;Discretionary Accounts,&#x201D;
&#x201C;Electronic Offer, Sale and Distribution of Shares&#x201D;,
&#x201C;Other Relationships&#x201D;, &#x201C;Stabilization,&#x201D; and
&#x201C;Passive Market Making&#x201D; and (c) the table showing the
number of Securities to be purchased by each Underwriter, (the
<font style="font-weight: bold">&#x201C;Underwriters'
Information&#x201D;);</font> and</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">(iv)&#xA0; Neither
the Prospectus nor any amendment or supplement thereto, as of its
issue date, at the time of any filing with the Commission pursuant
to Rule 424(b), at the Closing Date or at any Option Closing Date,
included, includes or will include an untrue statement of a
material fact or omitted, omits or will omit to state a material
fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not
misleading; provided, however, that this representation and
warranty shall not apply to the Underwriters'
Information.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">2.5.2&#xA0;
Disclosure of Agreements.</font> <font style="font-family: Times New Roman; font-size: 13px">The agreements and
documents described in the Registration Statement, the Disclosure
Package and the Prospectus conform in all material respects to the
descriptions thereof contained therein and there are no agreements
or other documents required by the Securities Act and the
Securities Act Regulations to be described in the Registration
Statement, the Disclosure Package and the Prospectus or to be filed
with the Commission as exhibits to the Registration Statement, that
have not been so described or filed. Each agreement or other
instrument (however characterized or described) to which the
Company or any of its direct and indirect subsidiaries, including
each entity disclosed or described in the Registration Statement,
the Disclosure Package and the Prospectus as being a subsidiary of
the Company (each, a <font style="font-weight: bold">&#x201C;Subsidiary&#x201D;</font> and,
collectively, the <font style="font-weight: bold">&#x201C;Subsidiaries&#x201D;)</font> is a party
or by which it is or may be bound or affected and (i) that is
referred to in the Registration Statement, the Disclosure Package
and the Prospectus, or (ii) is material to the business of the
Company or any Subsidiary, has been duly authorized and validly
executed by the Company or any Subsidiary, is in full force and
effect in all material respects and is enforceable against the
Company or any Subsidiary, and, to the Company's knowledge, the
other parties thereto, in accordance with its terms, except (x) as
such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors' rights
generally, (y) as enforceability of any indemnification or
contribution provision may be limited under the federal and state
securities laws, and (z) that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. None of such
agreements or instruments has been assigned by the Company or any
Subsidiary, and neither the Company, any Subsidiary nor, to the
Company's knowledge, any other party is in default thereunder and,
to the Company's knowledge, no event has occurred that, with the
lapse of time or the giving of notice, or both, would constitute a
default thereunder. To the best of the Company's knowledge,
performance by the Company or any Subsidiary of the material
provisions of such agreements or instruments will not result in a
violation of any existing applicable law, rule, regulation,
judgment, order or decree of any governmental or regulatory agency,
body or court, domestic or foreign, having jurisdiction over the
Company, any Subsidiary or any of their respective assets or
businesses (each, a <font style="font-weight: bold">&#x201C;Governmental
Entity&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>including, without limitation,
those relating to environmental laws and regulations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">2.5.3&#xA0;
Prior Securities Transactions.</font> <font style="font-family: Times New Roman; font-size: 13px">Since January 1,
2021, no securities of the Company have been sold by the Company or
by or on behalf of, or for the benefit of, any person or persons
controlling, controlled by or under common control with the
Company, except as disclosed in the Registration Statement, the
Disclosure Package and the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.5.4&#xA0; Regulations</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">The disclosures in
the Registration Statement, the Disclosure Package and the
Prospectus concerning the effects of federal, state, local and all
foreign laws, rules and regulations relating to the respective
businesses of the Company and its Subsidiaries as currently
conducted or contemplated are correct and complete in all material
respects and, to the Company's knowledge, no other such laws, rules
or regulations are required to be disclosed in the Registration
Statement, the Disclosure Package and the Prospectus which are not
so disclosed.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.5.5&#xA0; No Other Distribution of
Offering Materials</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company has
not, directly or indirectly, distributed and will not distribute
any offering material in connection with the Offering other than
any Preliminary Prospectus, the Disclosure Package, the Prospectus
and other materials, if any, permitted under the Securities Act and
consistent with Section 3.2 below.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.6&#xA0;
Changes After Dates in Registration Statement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.6.1&#xA0; No Material Adverse
Change</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Since the
respective dates as of which information is given in the
Registration Statement, the Disclosure Package and the Prospectus,
except as otherwise specifically stated or incorporated by
reference therein: (i) there has been no material adverse change in
the financial position or results of operations of the Company or
any Subsidiary, nor any change or development that, singularly or
in the aggregate, would involve a material adverse change or a
prospective material adverse change, in or affecting the condition
(financial or otherwise), results of operations, business, assets
or prospects of the Company or any Subsidiary (a <font style="font-weight: bold">&#x201C;Material Adverse Change&#x201D;);</font>
(ii) there have been no material transactions entered into by the
Company or any Subsidiary, other than as contemplated pursuant to
this Agreement; and (iii) no officer or director of the Company has
resigned from any position with the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.6.2&#xA0; Recent Securities
Transactions, etc</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Subsequent to the
respective dates as of which information is given in the
Registration Statement, the Disclosure Package and the Prospectus,
and except as may otherwise be indicated or contemplated herein or
disclosed in the Registration Statement, the Disclosure Package and
the Prospectus, the Company has not: (i) issued any securities,
other than securities issued pursuant to the Company's existing
equity incentive or stock option plans or shares of Common Stock
issuable upon the exercise of then outstanding options, warrants
and convertible securities, or incurred any liability or
obligation, direct or contingent, for borrowed money; or (ii)
declared or paid any dividend or made any other distribution on or
in respect to its capital stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.7&#xA0;
Disclosures in Commission Filings.</font> <font style="font-family: Times New Roman; font-size: 13px">Since October 1,
2019, (i) none of the Company's filings with the Commission
contained any untrue statement of a material fact or omitted to
state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were
made, not misleading; and (ii) the Company has made all filings
with the Commission required under the Exchange Act and the rules
and regulations of the Commission promulgated thereunder (the
<font style="font-weight: bold">&#x201C;Exchange Act
Regulations&#x201D;).</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.8&#xA0;
Independent Accountants.</font> <font style="font-family: Times New Roman; font-size: 13px">To the knowledge of
the Company, BDO USA, LLP (the <font style="font-weight: bold">&#x201C;Auditor&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>whose report is filed with the
Commission and incorporated in the Registration Statement, the
Disclosure Package and the Prospectus, is an independent registered
public accounting firm as required by the Securities Act and the
Securities Act Regulations and the Public Company Accounting
Oversight Board. The Auditor has not, during the periods covered by
the financial statements included in the Registration Statement,
the Disclosure Package and the Prospectus, provided to the Company
any non-audit services, as such term is used in Section 10A(g) of
the Exchange Act.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">2.9&#xA0; Financial Statements</font>,
<font style="font-weight: bold">etc.</font></font> <font style="font-family: Times New Roman; font-size: 13px">The financial
statements, including the notes thereto and supporting schedules
included or incorporated by reference in the Registration
Statement, the Disclosure Package and the Prospectus, fairly
present the financial position and the results of operations of the
Company at the dates and for the periods to which they apply; and
such financial statements have been prepared in conformity with
U.S. generally accepted accounting principles <font style="font-weight: bold">(&#x201C;GAAP&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>consistently applied throughout
the periods involved (provided that unaudited interim financial
statements are subject to year-end audit adjustments that are not
expected to be material in the aggregate and do not contain all
footnotes required by GAAP); and the supporting schedules included
or incorporated by reference in the Registration Statement, the
Disclosure Package and the Prospectus present fairly the
information required to be stated therein. Except as included or
incorporated by reference therein, no historical or pro forma
financial statements are required to be included or incorporated by
reference in the Registration Statement, the Disclosure Package or
the Prospectus under the Securities Act or the Securities Act
Regulations. The pro forma and pro forma as adjusted financial
information and the related notes, if any, included or incorporated
by reference in the Registration Statement, the Disclosure Package
and the Prospectus have been properly compiled and prepared in
accordance with the applicable requirements of the Securities Act
and the Securities Act Regulations and present fairly the
information shown therein, and the assumptions used in the
preparation thereof are reasonable and the adjustments used therein
are appropriate to give effect to the transactions and
circumstances referred to therein. All disclosures contained or
incorporated by reference in the Registration Statement, the
Disclosure Package or the Prospectus regarding &#x201C;non-GAAP
financial measures&#x201D; (as such term is defined by the rules and
regulations of the Commission), if any, comply with Regulation G of
the Exchange Act and Item 10 of Regulation S-K of the Securities
Act, to the extent applicable. Each of the Registration Statement,
the Disclosure Package and the Prospectus discloses all material
off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the
Company with unconsolidated entities or other persons that may have
a material current or future effect on the Company's financial
condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant
components of revenues or expenses. Except as disclosed in the
Registration Statement, the Disclosure Package and the Prospectus,
(a) neither the Company nor any of its Subsidiaries, including each
entity disclosed or described in the Registration Statement, the
Disclosure Package and the Prospectus as being a Subsidiary of the
Company, has incurred any material liabilities or obligations,
direct or contingent, or entered into any material transactions
other than in the ordinary course of business, (b) neither the
Company nor any of its Subsidiaries has declared or paid any
dividends or made any distribution of any kind with respect to its
capital stock, (c) there has not been any change in the capital
stock of the Company or any of its Subsidiaries, (d) other than in
the ordinary course of business and consistent with the Company's
prior policies, the Company has not made any grants under any stock
compensation plan, and (e) there has not been any material adverse
change in the long-term or short-term debt of the Company or any of
its Subsidiaries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">2.10&#xA0; Authorized Capital; Options</font>,
<font style="font-weight: bold">etc.</font></font> <font style="font-family: Times New Roman; font-size: 13px">The Company had, at
the date or dates indicated in the Registration Statement, the
Disclosure Package and the Prospectus, the duly authorized, issued
and outstanding capitalization as set forth therein. Based on the
assumptions stated in the Registration Statement, the Disclosure
Package and the Prospectus, the Company will have on the Closing
Date the adjusted stock capitalization set forth therein. Except as
set forth in, or contemplated by, the Registration Statement, the
Disclosure Package and the Prospectus, as of the Applicable Time
and on the Closing Date and any Option Closing Date, there will be
no stock options, warrants, or other rights to purchase or
otherwise acquire any authorized but unissued shares of Common
Stock of the Company or equity securities of any Subsidiary or any
security convertible or exercisable into shares of Common Stock of
the Company or equity securities of any Subsidiary, or any
contracts or commitments to issue or sell shares of Common Stock of
the Company or equity securities of any Subsidiary or any such
options, warrants, rights or convertible securities.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">2.11 Valid Issuance of Securities</font>,
<font style="font-weight: bold">etc.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.11.1 Outstanding
Securities</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">All issued and
outstanding securities of the Company issued prior to the
transactions contemplated by this Agreement have been duly
authorized and validly issued and are fully paid and
non-assessable; except as set forth in the Registration Statement,
the Disclosure Package and the Prospectus, the holders thereof have
no contractual rights of rescission or the ability to force the
Company to repurchase such securities with respect thereto, and are
not subject to personal liability by reason of being such holders;
and none of such securities were issued in violation of the
preemptive rights, rights of first refusal or rights of
participation of any holders of any security of the Company or
similar contractual rights granted by the Company. The authorized
shares of Common Stock conform in all material respects to all
statements relating thereto contained in the Registration
Statement, the Disclosure Package and the Prospectus. The offers
and sales of the outstanding shares of Common Stock, options,
warrants and other rights to purchase or exchange such securities
for shares of the Common Stock were at all relevant times either
registered under the Securities Act and the applicable state
securities or &#x201C;blue sky&#x201D; laws or, based in part on the
representations and warranties of the purchasers of such shares of
Common Stock, exempt from such registration requirements. The
description of the Company's stock option, stock bonus and other
stock plans or arrangements, and the options or other rights
granted thereunder, as described in the Registration Statement,
Disclosure Package and the Prospectus, accurately and fairly
present, in all material respects, the information required to be
shown with respect to such plans, arrangements, options and
rights.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.11.2 Securities Sold Pursuant to
this Agreement</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Securities have
been duly authorized for issuance and sale and, when issued and
paid for, will be validly issued, fully paid and non-assessable;
the holders thereof are not and will not be subject to personal
liability by reason of being such holders; the Securities are not
and will not be subject to the preemptive rights of any holders of
any security of the Company or similar contractual rights granted
by the Company; and all corporate action required to be taken for
the authorization, issuance and sale of the Securities has been
duly and validly taken. The Securities conform in all material
respects to all statements with respect thereto contained in the
Registration Statement, the Disclosure Package and the
Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.12
Registration Rights of Third Parties.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as set forth
in the Registration Statement, the Disclosure Package and the
Prospectus, no holders of any securities of the Company or any
options, warrants, rights or other securities exercisable for or
convertible or exchangeable into securities of the Company have the
right to require the Company to register any such securities of the
Company under the Securities Act or to include any such securities
in the Registration Statement or any other registration statement
to be filed by the Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.13
Validity and Binding Effect of Agreements.</font> <font style="font-family: Times New Roman; font-size: 13px">The execution,
delivery and performance of this Agreement has been duly and
validly authorized by the Company, and this Agreement, when
executed and delivered, will constitute, the valid and binding
agreement of the Company, enforceable against the Company in
accordance with its terms, except: (i) as such enforceability may
be limited by bankruptcy, insolvency, reorganization or similar
laws affecting creditors' rights generally; (ii) as enforceability
of any indemnification or contribution provision may be limited
under the federal and state securities laws; and (iii) that the
remedy of specific performance and injunctive and other forms of
equitable relief may be subject to the equitable defenses and to
the discretion of the court before which any proceeding therefor
may be brought.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">2.14 No Conflicts</font>, <font style="font-weight: bold">etc.</font></font> <font style="font-family: Times New Roman; font-size: 13px">The execution,
delivery and performance by the Company of this Agreement and all
ancillary documents, the consummation by the Company of the
transactions herein contemplated and the compliance by the Company
with the terms hereof and thereof do not and will not, with or
without the giving of notice or the lapse of time or both: (i)
result in a material breach of, or conflict with any of the terms
and provisions of, or constitute a material default under, or
result in the creation, modification, termination or imposition of
any lien, charge or encumbrance upon any property or assets of the
Company or any of its Subsidiaries pursuant to the terms of any
indenture, mortgage, deed of trust, loan agreement or any other
agreement or instrument to which the Company or any of its
Subsidiaries is a party or as to which any property of the Company
or any of its Subsidiaries is a party; (ii) result in any violation
of the provisions of the Company's Articles of Incorporation (as
the same have been amended or restated from time to time, the
<font style="font-weight: bold">&#x201C;Charter&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>the by-laws of the Company, the
certificate of incorporation of any Subsidiary or the bylaws of any
Subsidiary (as applicable); or (iii) violate any existing
applicable law, rule, regulation, judgment, order or decree of any
Governmental Entity as of the date hereof, except in the cases of
clauses (i) and (iii) for such breaches, conflicts or violations
which would not reasonably be expected to have a Material Adverse
Change.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.15
No Defaults; Violations.</font> <font style="font-family: Times New Roman; font-size: 13px">No material default
exists in the due performance and observance of any term, covenant
or condition of any material license, contract, indenture,
mortgage, deed of trust, note, loan or credit agreement, or any
other agreement or instrument evidencing an obligation for borrowed
money, or any other material agreement or instrument to which the
Company or any of its Subsidiaries is a party or by which the
Company or any of its Subsidiaries may be bound or to which any of
the properties or assets of the Company or any of its Subsidiaries
is subject. Neither the Company nor any of its Subsidiaries is (i)
in violation of any term or provision of its Charter or by-laws, or
(ii) in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental
Entity, except in the cases of clause (ii) for such violations
which would not reasonably be expected to result in a Material
Adverse Change.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.16
Corporate Power; Licenses; Consents.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.16.1 Conduct of
Business</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as described
in the Registration Statement, the Disclosure Package and the
Prospectus, each of the Company and its Subsidiaries has all
requisite corporate power and authority, and has all necessary
consents, authorizations, approvals, orders, licenses,
certificates, qualifications, registrations and permits
(collectively, the <font style="font-weight: bold">&#x201C;Authorizations&#x201D;)</font> of and
from all Governmental Entities that it needs as of the date hereof
to conduct its respective business as described in the Registration
Statement, the Disclosure Package and the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.16.2 Transactions Contemplated
Herein</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company has all
corporate power and authority to enter into this Agreement and to
carry out the provisions and conditions hereof, and all
Authorizations required in connection therewith have been obtained.
Except for the filing of an Additional Listing Application with the
NYSE American with respect to the sale of the Securities, no
Authorization of, and no filing with, any Governmental Entity is
required for the valid issuance, sale and delivery of the
Securities and the consummation of the transactions and agreements
contemplated by this Agreement and as contemplated by the
Registration Statement, the Disclosure Package and the Prospectus,
except with respect to applicable federal and state securities laws
and the rules and regulations of the Financial Industry Regulatory
Authority, Inc. <font style="font-weight: bold">(&#x201C;FINRA&#x201D;).</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.17
D&amp;O Questionnaires.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">To the
Company's knowledge, all information concerning each of the
Company's directors, officers and beneficial holders of 5% or more
of the Company's Common Stock immediately prior to the Offering
(the <font style="font-weight: bold">&#x201C;Insiders&#x201D;)</font>
as described in the Registration Statement, the Disclosure Package
and the Prospectus, as well as in the Lock-Up Agreements (as
defined in Section 2.27 below), provided to the Underwriters is
true and correct in all material respects and the Company has not
become aware of any information which would cause the information
disclosed in the Questionnaires to become inaccurate and incorrect
in any material respect.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.18
Litigation; Governmental Proceedings.</font> <font style="font-family: Times New Roman; font-size: 13px;">There is no
material action, suit, proceeding, inquiry, arbitration,
investigation, litigation or governmental proceeding pending or, to
the Company's knowledge, threatened against, or involving the
Company, any of its Subsidiaries or, to the Company's knowledge,
any executive officer or director which has not been disclosed in
the Registration Statement, the Disclosure Package and the
Prospectus which is required to be disclosed.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.19
Good Standing.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company has
been duly organized and is validly existing as a corporation and is
in good standing under the laws of its jurisdiction of
incorporation, and is duly qualified to do business and is in good
standing in each other jurisdiction in which its ownership or lease
of property or the conduct of business requires such qualification,
except where the failure to qualify, singularly or in the
aggregate, would not have or reasonably be expected to result in a
Material Adverse Change.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.20
Insurance.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company and
each of its Subsidiaries carries or is entitled to the benefits of
insurance (including, without limitation, as to directors and
officers insurance coverage), with reputable insurers, in such
amounts and covering such risks which the Company believes are
adequate, and all such insurance is in full force and effect. The
Company has no reason to believe that it or any of its Subsidiaries
will not be able (i) to renew its existing insurance coverage as
and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to
conduct its business as now conducted and at a cost that would not
result in a Material Adverse Change<font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.21
Transactions Affecting Disclosure to FINRA.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.21.1 Finder's Fees</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">Except as described
in the Registration Statement, the Disclosure Package and the
Prospectus, there are no claims, payments, arrangements, agreements
or understandings relating to the payment of a finder's, consulting
or origination fee by the Company or any Insider with respect to
the sale of the Securities hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company's
knowledge, any of its shareholders that may affect the
Underwriters' compensation, as determined by FINRA.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.21.2 Payments Within Six (6)
Months</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as described
in the Registration Statement, the Disclosure Package and the
Prospectus, the Company has not made any direct or indirect
payments (in cash, securities or otherwise) to: (i) any person, as
a finder's fee, consulting fee or otherwise, in consideration of
such person raising capital for the Company or introducing to the
Company persons who raised or provided capital to the Company; (ii)
any FINRA member; or (iii) any person or entity that has any direct
or indirect affiliation or association with any FINRA member,
within the six (6) months prior to the initial filing of the
Registration Statement, other than payments to the underwriters for
offerings under the Registration Statement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.21.3 Use of Proceeds</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">None of the net
proceeds of the Offering will be paid by the Company to any
participating FINRA member or its affiliates, except as
specifically authorized herein.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.21.4 FINRA
Affiliation</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">There is no (i)
officer or director of the Company, (ii) to the Company's
knowledge, any beneficial owner of 5% or more of any class of the
Company's securities or (iii) to the Company's knowledge, any
beneficial owner of the Company's unregistered equity securities
which were acquired during the 180-day period immediately preceding
the filing of the Registration Statement that is an affiliate or
associated person of a FINRA member participating in the Offering
(as determined in accordance with the rules and regulations of
FINRA).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.21.5 Information</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">All information
provided by the Company in its FINRA questionnaire to
Representative Counsel specifically for use by Representative
Counsel in connection with its Public Offering System filings (and
related disclosure) with FINRA is true, correct and complete in all
material respects.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.22
Foreign Corrupt Practices Act.</font> <font style="font-family: Times New Roman; font-size: 13px;">Neither the
Company, nor any of its Subsidiaries, nor, to the Company's
knowledge, any director, officer, agent, employee or affiliate of
the Company or any of its Subsidiaries nor, to the Company's
knowledge, any other person acting on behalf of the Company or any
of its Subsidiaries, has, directly or indirectly, given or agreed
to give any money, gift or similar benefit (other than legal price
concessions to customers in the ordinary course of business) to any
customer, supplier, employee or agent of a customer or supplier, or
official or employee of any governmental agency or instrumentality
of any government (domestic or foreign) or any political party or
candidate for office (domestic or foreign) or other person who was,
is, or may be in a position to help or hinder the business of the
Company or its Subsidiaries (or assist it in connection with any
actual or proposed transaction) that (i) might subject the Company
or any of its Subsidiaries to any material damage or penalty in any
civil, criminal or governmental litigation or proceeding, (ii) if
not given in the past, might have had a Material Adverse Change or
(iii) if not continued in the future, might adversely affect the
assets, business, operations or prospects of the Company or any of
its Subsidiaries. The Company and each of its Subsidiaries has
taken reasonable steps to ensure that its accounting controls and
procedures are sufficient to cause the Company to comply in all
material respects with the Foreign Corrupt Practices Act of 1977,
as amended.</font> </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.23
Compliance with OFAC.</font> <font style="font-family: Times New Roman; font-size: 13px">Neither the
Company, nor any of its Subsidiaries nor, to the Company's
knowledge, any director, officer, agent, employee or affiliate of
the Company or any of its Subsidiaries nor, to the Company's
knowledge, any other person acting on behalf of the Company or any
of its Subsidiaries, is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S.
Department of the Treasury (&#x201C;OFAC&#x201D;), and the Company
will not, directly or indirectly, use the proceeds of the Offering
hereunder, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other person
or entity, for the purpose of financing the activities of any
person currently subject to any U.S. sanctions administered by
OFAC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.24
Money Laundering Laws.</font> <font style="font-family: Times New Roman; font-size: 13px">The operations of
the Company and each of its Subsidiaries are and have been
conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and
Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any Governmental
Entity (collectively, the <font style="font-weight: bold">&#x201C;Money Laundering Laws&#x201D;);</font>
and no action, suit or proceeding by or before any Governmental
Entity involving the Company or any of its Subsidiaries with
respect to the Money Laundering Laws is pending or, to the best
knowledge of the Company, threatened.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.25
Forward-Looking Statements.</font> <font style="font-family: Times New Roman; font-size: 13px">No forward-looking
statement (within the meaning of Section 27A of the Securities Act
and Section 21E of the Exchange Act) contained in either the
Registration Statement, Disclosure Package or the Prospectus has
been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.26
Officers' Certificate.</font> <font style="font-family: Times New Roman; font-size: 13px">Any certificate
signed by any duly authorized officer of the Company and delivered
to you or to Representative Counsel shall be deemed a
representation and warranty by the Company to the Underwriters as
to the matters covered thereby.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.27
Lock-Up Agreements.</font> <font style="font-family: Times New Roman; font-size: 10"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Schedule 3</font> hereto contains a
complete and accurate list of the Company's officers, directors
and, to the Company's knowledge, holders of 5% or more of the
Company's Common Stock (collectively, the <font style="font-weight: bold">&#x201C;Lock-Up Parties&#x201D;).</font> The
Company has caused each of the Lock-Up Parties to deliver to the
Representative an executed Lock-Up Agreement, in the form attached
hereto as Exhibit A (the <font style="font-weight: bold">&#x201C;Lock-Up
Agreement&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>prior to the execution of this
Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.28
Subsidiaries.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company has no
subsidiaries.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.29
Related Party Transactions.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.29.1 Business Relationships</font>.
<font style="font-family: Times New Roman; font-size: 13px">There
are no business relationships or related party transactions
involving the Company or any other person required to be described
in the Registration Statement, the Disclosure Package and the
Prospectus that have not been described as
required.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.29.2 No Relationships with Customers
and Suppliers</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">No relationship,
direct or indirect, exists between or among the Company on the one
hand, and the directors, officers, 5% or greater stockholders,
customers or suppliers of the Company or any of the Company's
affiliates on the other hand, which is required to be described in
the Disclosure Package and the Prospectus or a document
incorporated by reference therein and which is not so
described.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.29.3 No Unconsolidated
Entities</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">There are no
transactions, arrangements or other relationships between and/or
among the Company, any of its affiliates (as such term is defined
in Rule 405 of the Securities Act) and any unconsolidated entity,
including, but not limited to, any structure finance, special
purpose or limited purpose entity that could reasonably be expected
to materially affect the Company's liquidity or the availability of
or requirements for its capital resources required to be described
in the Disclosure Package and the Prospectus or a document
incorporated by reference therein which have not been described as
required.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.29.4 No Loans or Advances to
Affiliates</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">There are no
outstanding loans, advances (except normal advances for business
expenses in the ordinary course of business) or guarantees or
indebtedness by the Company to or for the benefit of any of the
officers or directors of the Company or any of their respective
family members, except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.30
Board of Directors.</font> <font style="font-family: Times New Roman; font-size: 13px">The qualifications
of the persons serving as members of the Company's Board of
Directors and the overall composition of the Board comply with the
Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act
of 2002 and the rules promulgated thereunder (the <font style="font-weight: bold">&#x201C;Sarbanes-Oxley Act&#x201D;)</font>
applicable to the Company and the listing rules of the NYSE
American. At least one member of the Audit Committee of the Board
of Directors of the Company qualifies as an &#x201C;audit committee
financial expert,&#x201D; as such term is defined under Regulation
S-K and the listing rules of the NYSE American. In addition, 50% of
the persons serving on the Board of Directors qualify as
&#x201C;independent,&#x201D; as defined under the listing rules of
the NYSE American.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.31
Sarbanes-Oxley Compliance.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.31.1 Disclosure
Controls</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as disclosed
in the Registration Statement, the Disclosure Package and the
Prospectus, the Company has developed and currently maintains
disclosure controls and procedures that comply with Rule 13a-15 or
15d-15 under the Exchange Act Regulations, and such controls and
procedures are effective to the extent or except as otherwise
disclosed in the Registration Statement, the Disclosure Package and
the Prospectus to ensure that all material information concerning
the Company will be made known on a timely basis to the individuals
responsible for the preparation of the Company's Exchange Act
filings and other public disclosure documents.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">2.31.2 Compliance</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">The Company is, or
at the Applicable Time and on the Closing Date will be, in material
compliance with the provisions of the Sarbanes-Oxley Act applicable
to it, and has implemented or will implement such programs and
taken reasonable steps to ensure the Company's future compliance
(not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley
Act.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.32
Accounting Controls.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as disclosed
in the Registration Statement, the Disclosure Package and the
Prospectus, the Company and each of its Subsidiaries maintains
systems of &#x201C;internal control over financial reporting&#x201D;
(as defined under Rules 13a-15 and 15d-15 under the Exchange Act
Regulations ) that comply in all material respects with the
requirements of the Exchange Act and have been designed by, or
under the supervision of, their respective principal executive and
principal financial officers, or persons performing similar
functions, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP,
including, but not limited to, internal accounting controls
sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management's general or specific
authorizations; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP
and to maintain asset accountability; (iii) access to assets is
permitted only in accordance with management's general or specific
authorization; and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. Except
as disclosed in the Registration Statement, the Disclosure Package
and the Prospectus, the Company is not aware of any material
weaknesses in its internal controls. The Auditor and the Audit
Committee of the Board of Directors of the Company have been
advised of: (i) all significant deficiencies and material
weaknesses in the design or operation of internal controls over
financial reporting which are known to the Company's management and
that have adversely affected or are reasonably likely to adversely
affect the Company' ability to record, process, summarize and
report financial information; and (ii) any fraud known to the
Company's management, whether or not material, that involves
management or other employees who have a significant role in the
Company's internal controls over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.33
No Investment Company Status.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company is not
and, after giving effect to the Offering and the application of the
proceeds thereof as described in the Registration Statement, the
Disclosure Package and the Prospectus, will not be, required to
register as an &#x201C;investment company,&#x201D; as defined in the
Investment Company Act of 1940, as amended.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.34
No Labor Disputes.</font> <font style="font-family: Times New Roman; font-size: 13px">No labor dispute
with the employees of the Company or any of its Subsidiaries exists
or, to the knowledge of the Company, is imminent. The Company is
not aware that any key employee or significant group of employees
of the Company or any Subsidiary plans to terminate employment with
the Company or such Subsidiary.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.35
Intellectual Property Rights.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company and
each of its Subsidiaries owns or possesses or has valid rights to
use all patents, patent applications, trademarks, service marks,
trade names, trademark registrations, service mark registrations,
copyrights, licenses, inventions, trade secrets software,
databases, know-how, internet domain names, other unpatented and/or
un-patentable proprietary confidential information systems,
processes or procedures and similar rights <font style="font-weight: bold">(&#x201C;Intellectual Property
Rights&#x201D;)</font> necessary for the conduct of the business of
the Company or such Subsidiary as currently carried on and as
described in the Registration Statement, the Disclosure Package and
the Prospectus. The Intellectual Property licenses described in the
Registration Statement, Disclosure Package and the Prospectus are
validly executed by, binding upon and enforceable against the
Company in accordance with their respective terms. To the knowledge
of the Company, no action or use by the Company or any of its
Subsidiaries necessary for the conduct of their respective
businesses as currently carried on and as described in the
Registration Statement and the Prospectus will involve or give rise
to any infringement of, or license or similar fees for, any
Intellectual Property Rights of others. The Company has not
received any notice alleging any such infringement, fee or conflict
with asserted Intellectual Property Rights of others. Except as
would not reasonably be expected to result, individually or in the
aggregate, in a Material Adverse Change or as otherwise as
disclosed in the Registration Statement, the Disclosure Package and
the Prospectus (A) there is no pending or, to the knowledge of the
Company, threatened action, suit, proceeding or claim by others
challenging the rights of the Company or any of its Subsidiaries in
or to any such Intellectual Property Rights, and the Company is
unaware of any facts which would form a reasonable basis for any
such claim, that would, individually or in the aggregate, together
with any other claims in this Section 2.35, reasonably be expected
to result in a Material Adverse Change; (B) the Intellectual
Property Rights owned by the Company and, to the knowledge of the
Company, the Intellectual Property Rights licensed to the Company
have not been adjudged by a court of competent jurisdiction invalid
or unenforceable, in whole or in part, and there is no pending or,
to the Company's knowledge, threatened action, suit, proceeding or
claim by others challenging the validity or scope of any such
Intellectual Property Rights, and the Company is unaware of any
facts which would form a reasonable basis for any such claim that
would, individually or in the aggregate, together with any other
claims in this Section 2.35, reasonably be expected to result in a
Material Adverse Change; (C) there is no pending or, to the
Company's knowledge, threatened action, suit, proceeding or claim
by others that the Company infringes, misappropriates or otherwise
violates any Intellectual Property Rights or other proprietary
rights of others, the Company has not received any written notice
of such claim and the Company is unaware of any other facts which
would form a reasonable basis for any such claim that would,
individually or in the aggregate, together with any other claims in
this Section 2.35, reasonably be expected to result in a Material
Adverse Change; and (D) to the Company's knowledge, no employee of
the Company is in or has ever been in violation in any material
respect of any term of any employment contract, patent disclosure
agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or
any restrictive covenant to or with a former employer where the
basis of such violation relates to such employee's employment with
the Company, or actions undertaken by the employee while employed
with the Company and could reasonably be expected to result,
individually or in the aggregate, in a Material Adverse Change. To
the Company's knowledge, all material technical information
developed by and belonging to the Company which has not been
patented has been kept confidential. The Company is not a party to
or bound by any options, licenses or agreements with respect to the
Intellectual Property Rights of any other person or entity that are
required to be set forth in the Registration Statement, the
Disclosure Package and the Prospectus and are not described
therein. The Registration Statement, the Disclosure Package and the
Prospectus contain in all material respects the same description of
the matters set forth in the preceding sentence. None of the
technology employed by the Company has been obtained or is being
used by the Company in violation of any contractual obligation
binding on the Company or, to the Company's knowledge, any of its
officers, directors or employees, or otherwise in violation of the
rights of any persons.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.36
Taxes.</font> <font style="font-family: Times New Roman; font-size: 13px">Each of the Company
and its Subsidiaries has filed all returns (as hereinafter defined)
required to be filed with taxing authorities prior to the date
hereof or has duly obtained extensions of time for the filing
thereof. Each of the Company and its Subsidiaries has paid all
taxes (as hereinafter defined) shown as due on such returns that
were filed and has paid all taxes imposed on or assessed against
the Company or such respective Subsidiary. The provisions for taxes
payable, if any, shown on the financial statements filed with or as
part of the Registration Statement are sufficient for all accrued
and unpaid taxes, whether or not disputed, and for all periods to
and including the dates of such consolidated financial statements.
Except as disclosed in writing to the Underwriters, (i) no issues
have been raised (and are currently pending) by any taxing
authority in connection with any of the returns or taxes asserted
as due from the Company or its Subsidiaries, and (ii) no waivers of
statutes of limitation with respect to the returns or collection of
taxes have been given by or requested from the Company or its
Subsidiaries. The term <font style="font-weight: bold">&#x201C;taxes&#x201D;</font> mean all federal,
state, local, foreign and other net income, gross income, gross
receipts, sales, use, ad valorem, transfer, franchise, profits,
license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium,
property, windfall profits, customs, duties or other taxes, fees,
assessments or charges of any kind whatever, together with any
interest and any penalties, additions to tax or additional amounts
with respect thereto. The term <font style="font-weight: bold">&#x201C;returns&#x201D;</font> means all returns,
declarations, reports, statements and other documents required to
be filed in respect to taxes.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.37
Compliance with Environmental Laws.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as described
in the Registration Statement, the Disclosure Package and the
Prospectus, (i) neither the Company nor any of its Subsidiaries is
in material violation of any federal, state, local or foreign
statute, law, rule, regulation, ordinance, code, policy or rule of
common law or any judicial or administrative interpretation
thereof, including any judicial or administrative order, consent,
decree or judgment, relating to pollution or protection of human
health, the environment (including, without limitation, ambient
air, surface water, groundwater, land surface or subsurface strata)
or wildlife, including, without limitation, laws and regulations
relating to the release or threatened release of chemicals,
pollutants, contaminants, wastes, toxic substances, hazardous
substances, petroleum or petroleum products (collectively,
<font style="font-weight: bold">&#x201C;Hazardous
Materials&#x201D;)</font> or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials (collectively, <font style="font-weight: bold">&#x201C;Environmental Laws )</font>,<font style="font-weight: bold">&#xA0;</font>(ii) the Company and each of its
Subsidiaries has all material permits, authorizations and approvals
required under any applicable Environmental Laws and is in
compliance with their requirements, (iii) there are no pending or,
to the Company's knowledge, threatened administrative, regulatory
or judicial actions, suits, demands, demand letters, claims, liens,
notices of noncompliance or violation, investigation or proceedings
relating to any Environmental Law against the Company or any of its
Subsidiaries and (iv) to the Company's knowledge, there are no
events or circumstances that might reasonably be expected to form
the basis of an order for clean-up or remediation, or an action,
suit or proceeding by any private party or governmental body or
agency, against or affecting the Company or any of its Subsidiaries
relating to Hazardous Materials or any Environmental
Laws.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.38
ERISA Compliance.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company and any
&#x201C;employee benefit plan&#x201D; (as defined under the Employee
Retirement Income Security Act of 1974, as amended, and the
regulations and published interpretations thereunder (collectively,
<font style="font-weight: bold">&#x201C;ERISA&#x201D;))</font>
established or maintained by the Company or its &#x201C;ERISA
Affiliates&#x201D; (as defined below) are in compliance in all
material respects with ERISA. <font style="font-weight: bold">&#x201C;ERISA Affiliate&#x201D;</font> means,
with respect to the Company, any member of any group of
organizations described in Sections 414(b), (c),(m) or (o) of the
Internal Revenue Code of 1986, as amended, and the regulations and
published interpretations thereunder (the <font style="font-weight: bold">&#x201C;Code&#x201D;)</font> of which the Company
is a member. No &#x201C;reportable event&#x201D; (as defined under
ERISA) has occurred or is reasonably expected to occur with respect
to any &#x201C;employee benefit plan&#x201D; established or
maintained by the Company or any of its ERISA Affiliates. No
&#x201C;employee benefit plan&#x201D; established or maintained by
the Company or any of its ERISA Affiliates, if such &#x201C;employee
benefit plan&#x201D; were terminated, would have any &#x201C;amount
of unfunded benefit liabilities&#x201D; (as defined under ERISA).
Neither the Company nor any of its ERISA Affiliates has incurred or
reasonably expects to incur any material liability under (i) Title
IV of ERISA with respect to termination of, or withdrawal from, any
&#x201C;employee benefit plan&#x201D; or (ii) Sections 412, 4971,
4975 or 4980B of the Code. Each &#x201C;employee benefit plan&#x201D;
established or maintained by the Company or any of its ERISA
Affiliates that is intended to be qualified under Section 401(a) of
the Code is so qualified and, to the knowledge of the Company,
nothing has occurred, whether by action or failure to act, which
would cause the loss of such qualification. The execution of this
Agreement, or consummation of the Offering does not constitute a
triggering event under any employee benefit plan or any other
employment contract, whether or not legally enforceable, which
(either alone or upon the occurrence of any additional or
subsequent event) will or may result in any payment (of severance
pay or otherwise), acceleration, increase in vesting, or increase
in benefits to any current or former participant, employee or
director of the Company other than an event that is not material to
the financial condition or business of the Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.39
Compliance with Laws.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company and
each of its Subsidiaries: (A) is and at all times has been in
compliance with all statutes, rules, or regulations applicable to
the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any
product manufactured or distributed by the Company <font style="font-weight: bold">(&#x201C;Applicable
Laws&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>except as could not, individually
or in the aggregate, reasonably be expected to have a Material
Adverse Change; (B) possesses all material Authorizations and such
Authorizations are valid and in full force and effect and are not
in material violation of any term of any such Authorizations; (C)
has not received notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action
from any Governmental Entity or third party alleging that any
product operation or activity is in violation of any Applicable
Laws or Authorizations and has no knowledge that any such
governmental authority or third party is considering any such
claim, litigation, arbitration, action, suit, investigation or
proceeding; (D) has not received notice that any Governmental
Entity has taken, is taking or intends to take action to limit,
suspend, modify or revoke any Authorizations and has no knowledge
that any such governmental authority is considering such action;
and (E) has filed, obtained, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments as required by any
Applicable Laws or Authorizations and that all such reports,
documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete and correct
on the date filed (or were corrected or supplemented by a
subsequent submission).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.40
Smaller Reporting Company.</font> <font style="font-family: Times New Roman; font-size: 13px">As of the effective
date, or deemed effective date, of the Registration Statement, the
Company was a &#x201C;smaller reporting company,&#x201D; as defined
in Rule 12b-2 of the Exchange Act Regulations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.41
Industry Data.</font> <font style="font-family: Times New Roman; font-size: 13px">The statistical and
market-related data included in each of the Registration Statement,
the Disclosure Package and the Prospectus are based on or derived
from sources that the Company reasonably and in good faith believes
are reliable and accurate or represent the Company's good faith
estimates that are made on the basis of data derived from such
sources.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.42
Margin Securities.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company does
not own any &#x201C;margin securities&#x201D; as that term is defined
in Regulation U of the Board of Governors of the Federal Reserve
System (the <font style="font-weight: bold">&#x201C;Federal Reserve
Board&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>and none of the proceeds of
Offering will be used, directly or indirectly, for the purpose of
purchasing or carrying any margin security, for the purpose of
reducing or retiring any indebtedness which was originally incurred
to purchase or carry any margin security or for any other purpose
which might cause any of the shares of Common Stock to be
considered a &#x201C;purpose credit&#x201D; within the meanings of
Regulation T, U or X of the Federal Reserve Board.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.43
Integration.</font> <font style="font-family: Times New Roman; font-size: 13px">Neither the
Company, nor any of its affiliates, nor any person acting on its or
their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under
circumstances that would cause the Offering to be integrated with
prior offerings by the Company for purposes of the Securities Act
that would require the registration of any such securities under
the Securities Act.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.44
Title.</font> <font style="font-family: Times New Roman; font-size: 13px">Except as described
in the Registration Statement, the Disclosure Package and the
Prospectus, the Company and each of its Subsidiaries has good and
marketable title in fee simple to, or has valid rights to lease or
otherwise use, all items of real or personal property that are
material to its respective business, free and clear of all liens,
encumbrances, security interests, claims and defects that do not,
singularly or in the aggregate, materially affect the business of
the Company or its Subsidiaries and do not interfere with the use
made of such property by the Company or its Subsidiaries; and all
of the leases and subleases material to the business of the Company
and each of its Subsidiaries, and under which the Company or any of
its Subsidiaries holds properties described in the Registration
Statement, the Disclosure Package and the Prospectus, are, to the
Company's knowledge in full force and effect, and neither the
Company nor any of its Subsidiaries has received any notice of any
material claim of any sort that have been asserted by anyone
adverse to the rights of the Company or such Subsidiaries under any
of the leases or subleases mentioned above, or affecting or
questioning the rights of the Company or such Subsidiaries to the
continued possession of the leased or subleased premises under any
such lease or sublease, which would result in a Material Adverse
Change<font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.45
Confidentiality and Non-Competitions.</font> <font style="font-family: Times New Roman; font-size: 13px">To the Company's
knowledge, no director, officer, key employee or consultant of the
Company is subject to any confidentiality, non-disclosure,
non-competition agreement or non-solicitation agreement with any
employer or prior employer that could materially affect his ability
to be and act in his respective capacity of the Company or be
expected to result in a Material Adverse Change.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2.46
Potential Products; FDA; EMEA.</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Except
as described in the Registration Statement, the Disclosure Package
and the Prospectus, the Company possesses all certificates,
authorizations and permits issued by the appropriate federal, state
or foreign regulatory authorities necessary to conduct its business
as currently conducted, including without limitation all such
certificates, authorizations and permits required by the United
States Food and Drug Administration (the <font style="font-weight: bold">&#x201C;FDA&#x201D;)</font> or any other federal,
state or foreign agencies or bodies engaged in the regulation of
pharmaceuticals or biohazardous materials, except where the failure
to so possess such certificates, authorizations and permits,
individually or in the aggregate, would not reasonably be expected
to result in a Material Adverse Effect. Except as described in the
Registration Statement, the Disclosure Package and the Prospectus,
the Company has not received any written notice of proceedings
relating to the revocation or modification of any such certificate,
authorization or permit which, individually or in the aggregate, if
the subject of an unfavorable decision, ruling or finding, would
reasonably be expected to have a Material Adverse
Effect.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Except
to the extent disclosed in the Registration Statement, the
Disclosure Package and the Prospectus, the Company has not received
any written notices or statements from the FDA, the European
Medicines Agency (the <font style="font-weight: bold">&#x201C;EMEA&#x201D;)</font> or any other
governmental agency that (i) any drug candidate of the Company
described in the Registration Statement, the Disclosure Package and
the Prospectus (each a <font style="font-weight: bold">&#x201C;Potential Product&#x201D;)</font> may or
will be rejected or determined to be non-approvable; (ii) a delay
in time for review and/or approval of a marketing authorization
application or marketing approval application in any jurisdiction
for any Potential Product is or may be required, requested or being
implemented; (iii) one or more clinical studies for any Potential
Product shall or may be requested or required in addition to the
clinical studies submitted to the FDA prior to the date hereof as a
precondition to or condition of issuance or maintenance of a
marketing approval for any Potential Product; (iv) any license,
approval, permit or authorization to conduct any clinical trial of
or market any product or Potential Product of the Company has been,
will be or may be suspended, revoked, modified or limited, except
in the cases of clauses (i), (ii), (iii) and (iv) where such
rejections, determinations, delays, requests, suspensions,
revocations, modifications or limitations would not reasonably be
expected to have, individually or in the aggregate, a Material
Adverse Effect.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Except
to the extent disclosed in the Registration Statement, the
Disclosure Package and the Prospectus, to the Company's knowledge,
the preclinical and clinical testing, application for marketing
approval of, manufacture, distribution, promotion and sale of the
products and Potential Products of the Company is in compliance, in
all material respects, with all laws, rules and regulations
applicable to such activities, including without limitation
applicable good laboratory practices, good clinical practices and
good manufacturing practices, except for such non-compliance as
would not reasonably be expected to have, individually or in the
aggregate, have a Material Adverse Effect. The descriptions of the
results of such tests and trials contained in the Registration
Statement, the Disclosure Package and the Prospectus are complete
and accurate in all material respects such that there would be no
untrue statement of a material fact or omission of a material fact
necessary to make the statements in the Registration Statement, the
Disclosure Package and the Prospectus, in light of the
circumstances under which they are made, not misleading. The
Company is not aware of any studies, tests or trial the results of
which reasonably call into question the results of the tests and
trials conducted by or on behalf of the Company that are described
or referred to in the Registration Statement, the Disclosure
Package and the Prospectus. Except to the extent disclosed in the
Registration Statement, the Disclosure Package and the Prospectus,
the Company has not received written notice of adverse finding,
warning letter or clinical hold notice from the FDA or any non-U.S.
counterpart of any of the foregoing, or any untitled letter or
other correspondence or notice from the FDA or any other
governmental authority or agency or any institutional or ethical
review board alleging or asserting noncompliance with any law, rule
or regulation applicable in any jurisdiction, except notices,
letters, and correspondences and non-U.S. counterparts thereof
alleging or asserting such noncompliance as would not reasonably be
expected to have, individually or in the aggregate, have a Material
Adverse Effect. Except to the extent disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company
has not, either voluntarily or involuntarily, initiated, conducted
or issued, or caused to be initiated, conducted or issued, any
recall, field correction, market withdrawal or replacement, safety
alert, warning, &#x201C;dear doctor&#x201D; letter, investigator
notice, or other notice or action relating to an alleged or
potential lack of safety or efficacy of any product or Potential
Product of the Company, any alleged product defect of any product
or Potential Product of the Company, or any violation of any
material applicable law, rule, regulation or any clinical trial or
marketing license, approval, permit or authorization for any
product or potential product of the Company, and the Company is not
aware of any facts or information that would cause it to initiate
any such notice or action and has no knowledge or reason to believe
that the FDA, the EMEA or any other governmental agency or
authority or any institutional or ethical review board or other
non-governmental authority intends to impose, require, request or
suggest such notice or action.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.&#xA0;</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">COVENANTS
OF THE COMPANY.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company
covenants and agrees as follows:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.1
Amendments to Registration Statement.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
deliver to the Representative, prior to filing, any amendment or
supplement to the Registration Statement, any Preliminary
Prospectus, Disclosure Package or Prospectus proposed to be filed
and shall not file any such document to which the Representative
shall reasonably object in writing.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.2
Federal Securities Laws.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">3.2.1 Compliance</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">The Company,
subject to Section 3.2.2, shall comply with the requirements of
Rule 424(b) and Rule 430B of the Securities Act Regulations, and
will notify the Representative promptly, and confirm the notice in
writing, (i) when any post-effective amendment to the Registration
Statement or any amendment or supplement to any Preliminary
Prospectus, the Disclosure Package or the Prospectus shall have
been filed and when any post-effective amendment to the
Registration Statement shall become effective; (ii) of the receipt
of any comments from the Commission; (iii) of any request by the
Commission for any amendment to the Registration Statement or any
amendment or supplement to any Preliminary Prospectus, the
Disclosure Package or the Prospectus or for additional information;
(iv) of the issuance by the Commission of any stop order suspending
the effectiveness of the Registration Statement or any
post-effective amendment or of any order preventing or suspending
the use of any Preliminary Prospectus, the Disclosure Package or
the Prospectus, or of the suspension of the qualification of the
Securities for offering or sale in any jurisdiction, or of the
initiation or threatening of any proceedings for any of such
purposes or of any examination pursuant to Section 8(d) or 8(e) of
the Securities Act concerning the Registration Statement; and (v)
if the Company becomes the subject of a proceeding under Section 8A
of the Securities Act in connection with the Offering of the
Securities. The Company shall effect all filings required under
Rule 424(b) of the Securities Act Regulations, in the manner and
within the time period required by Rule 424(b) (without reliance on
Rule 424(b)(8)), and shall take such steps as it deems necessary to
ascertain promptly whether the form of prospectus transmitted for
filing under Rule 424(b) was received for filing by the Commission
and, in the event that it was not, it will promptly file such
prospectus. The Company shall use its best efforts to prevent the
issuance of any stop order, prevention or suspension and, if any
such order is issued, to obtain the lifting thereof at the earliest
possible moment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">3.2.2 Continued
Compliance</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
comply with the Securities Act, the Securities Act Regulations, the
Exchange Act and the Exchange Act Regulations so as to permit the
completion of the distribution of the Securities as contemplated in
this Agreement and in the Registration Statement, the Disclosure
Package and the Prospectus. If at any time when a prospectus
relating to the Securities is (or, but for the exception afforded
by Rule 172 of the Securities Act Regulations <font style="font-weight: bold">(&#x201C;Rule 172&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>would be) required by the
Securities Act to be delivered in connection with sales of the
Securities, any event shall occur or condition shall exist as a
result of which it is necessary, in the opinion of counsel for the
Underwriters or for the Company, to (i) amend the Registration
Statement in order that the Registration Statement will not include
an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the
statements therein not misleading; (ii) amend or supplement the
Disclosure Package or the Prospectus in order that the Disclosure
Package or the Prospectus, as the case may be, will not include any
untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein not
misleading in the light of the circumstances existing at the time
it is delivered to a purchaser or (iii) amend the Registration
Statement or amend or supplement the Disclosure Package or the
Prospectus, as the case may be, in order to comply with the
requirements of the Securities Act or the Securities Act
Regulations, the Company will promptly (A) give the Representative
notice of such event; (B) prepare any amendment or supplement as
may be necessary to correct such statement or omission or to make
the Registration Statement, the Disclosure Package or the
Prospectus comply with such requirements and, a reasonable amount
of time prior to any proposed filing or use, furnish the
Representative with copies of any such amendment or supplement and
(C) file with the Commission any such amendment or supplement;
provided that the Company shall not file or use any such amendment
or supplement to which the Representative or counsel for the
Underwriters shall reasonably object. The Company will furnish to
the Underwriters such number of copies of such amendment or
supplement as the Underwriters may reasonably request. The Company
has given the Representative notice of any filings made pursuant to
the Exchange Act or the Exchange Act Regulations within 48 hours
prior to the Applicable Time; the Company will give the
Representative notice of its intention to make any such filing from
the Applicable Time to the Closing Date and will furnish the
Representative with copies of any such documents a reasonable
amount of time prior to such proposed filing, as the case may be,
and will not file or use any such document to which the
Representative or counsel for the Underwriters shall reasonably
object.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">3.2.3 Exchange Act
Registration</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">For a period of
three (3) years after the date of this Agreement, the Company shall
use its reasonable best efforts to maintain the registration of the
Common Stock under the Exchange Act, provided that such provision
shall not prevent a sale, merger or similar transaction involving
the Company. The Company shall not, for a period of three (3) years
after the date of this Agreement, deregister the Common Stock under
the Exchange Act without the prior written consent of the
Representative, which consent shall not be unreasonably
withheld.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">3.2.4 Free Writing
Prospectuses</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company agrees
that, unless it obtains the prior written consent of the
Representative, it shall not make any offer relating to the
Securities that would constitute an Issuer Free Writing Prospectus
or that would otherwise constitute a &#x201C;free writing
prospectus,&#x201D; or a portion thereof, required to be filed by
the Company with the Commission or retained by the Company under
Rule 433; provided that the Representative shall be deemed to have
consented to each Issuer General Use Free Writing Prospectus hereto
and any &#x201C;road show that is a written communication&#x201D;
within the meaning of Rule 433(d)(8)(i) that has been reviewed by
the Representative. The Company represents that it has treated or
agrees that it will treat each such free writing prospectus
consented to, or deemed consented to, by the Underwriters as an
&#x201C;issuer free writing prospectus,&#x201D; as defined in Rule
433, and that it has complied and will comply with the applicable
requirements of Rule 433 with respect thereto, including timely
filing with the Commission where required, legending and record
keeping. If at any time following issuance of an Issuer Free
Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted
or would conflict with the information contained in the
Registration Statement or included or would include an untrue
statement of a material fact or omitted or would omit to state a
material fact necessary in order to make the statements therein, in
the light of the circumstances existing at that subsequent time,
not misleading, the Company will promptly notify the Underwriters
and will promptly amend or supplement, at its own expense, such
Issuer Free Writing Prospectus to eliminate or correct such
conflict, untrue statement or omission.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.3
Delivery to the Underwriters of Registration Statements.</font>
<font style="font-family: Times New Roman; font-size: 13px">The Company has
delivered or made available or shall deliver or make available to
the Representative and counsel for the Representative, if
requested, without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including
exhibits filed therewith) and signed copies of all consents and
certificates of experts, and will also deliver to the Underwriters,
without charge, a conformed copy of the Registration Statement as
originally filed and each amendment thereto (without exhibits) for
each of the Underwriters. The copies of the Registration Statement
and each amendment thereto furnished to the Underwriters will be
identical to the electronically transmitted copies thereof filed
with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.4
Delivery to the Underwriters of Prospectuses.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company has
delivered or made available or will deliver or make available to
each Underwriter, without charge, as many copies of each
Preliminary Prospectus, Disclosure Package and the Prospectus as
such Underwriter reasonably requested, and the Company hereby
consents to the use of such copies for purposes permitted by the
Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the
Securities is (or, but for the exception afforded by Rule 172 of
the Securities Act Regulations, would be) required to be delivered
under the Securities Act, such number of copies of the Prospectus
(as amended or supplemented) as such Underwriter may reasonably
request. The Preliminary Prospectus, the Disclosure Package, the
Prospectus and any amendments or supplements thereto furnished to
the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation
S-T.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.5
Listing.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
use its reasonable best efforts to maintain the listing of the
Common Stock on the NYSE American for at least three years from the
date of this Agreement; provided that such provision shall not
prevent a sale, merger or similar transaction involving the
Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.6
Payment of Expenses.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company hereby
agrees to pay on each of the Closing Date and the Option Closing
Date, if any, to the extent not paid at the Closing Date, all
expenses incident to the performance of the obligations of the
Company under this Agreement, including, but not limited to: (a)
all filing fees and communication expenses relating to the
registration of Securities to be issued and sold in the Offering
with the Commission; (b) all Public Offering System filing fees
associated with the review of the Offering by FINRA; (c) all fees
and expenses relating to the listing of the Securities on the NYSE
American, including any fees charged by DTC; (d) all fees, expenses
and disbursements relating to the registration or qualification of
the Securities under the &#x201C;blue sky&#x201D; securities laws of
such states and other jurisdictions as the Representative may
reasonably designate (including, without limitation, all required
filing and registration fees, and the reasonable fees and
disbursements of &#x201C;blue sky&#x201D; counsel which will be
Representative Counsel); (e) all fees, expenses and disbursements
relating to the registration, qualification or exemption of the
Securities under the securities laws of such foreign jurisdictions
as the Representative may reasonably designate; (f) the costs of
all mailing and printing of the underwriting documents (including,
without limitation, the Underwriting Agreement, any Blue Sky
Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers' Agreement, Underwriters' Questionnaire and Power
of Attorney), Registration Statements, Preliminary Prospectuses,
Disclosure Packages and Prospectuses and all amendments,
supplements and exhibits thereto and as many Preliminary
Prospectuses and Prospectuses as the Representative may reasonably
deem necessary; (g) the costs of preparing, printing and delivering
certificates representing the Securities; (h) fees and expenses of
the Company's transfer agent; (j) stock transfer and/or stamp
taxes, if any, payable upon the transfer of securities from the
Company to the Underwriters; (k) the fees and expenses of the
Company's accountants; (l) the fees and expenses of the Company's
legal counsel and other agents and representatives; and (m) $65,000
for the actual fees and expenses incurred by the Representative,
including for legal fees of the Representative Counsel or $25,000
if the Offering is not consummated. The Representative may deduct
from the net proceeds of the Offering payable to the Company on the
Closing Date, or the Option Closing Date, if any, the expenses set
forth herein to be paid by the Company to the
Underwriters.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.7
[Reserved]</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.8
Application of Net Proceeds.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
apply the net proceeds from the Offering received by it in a manner
consistent with the application thereof described under the caption
&#x201C;Use of Proceeds&#x201D; in the Registration Statement, the
Disclosure Package and the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.9
Stabilization.</font> <font style="font-family: Times New Roman; font-size: 13px">Neither the Company
nor, to its knowledge, any of its employees, directors or
shareholders (without the consent of the Representative) has taken
or shall take, directly or indirectly, any action designed to or
that has constituted or that might reasonably be expected to cause
or result in, under Regulation M of the Exchange Act, or otherwise,
stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of the
Securities.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.10
Internal Controls.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
maintain and shall cause each of its Subsidiaries to maintain a
system of internal accounting controls sufficient to provide
reasonable assurances that: (i) transactions are executed in
accordance with management's general or specific authorization;
(ii) transactions are recorded as necessary in order to permit
preparation of financial statements in accordance with GAAP and to
maintain accountability for assets; (iii) access to assets is
permitted only in accordance with management's general or specific
authorization; and (iv) the recorded accountability for assets is
compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any
differences.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.11
Accountants.</font> <font style="font-family: Times New Roman; font-size: 13px">As of the date of
this Agreement, the Company shall retain an independent registered
public accounting firm, as required by the Securities Act and the
Regulations and the Public Company Accounting Oversight Board,
reasonably acceptable to the Representative. The Representative
acknowledges that the Auditor is acceptable to the
Representative.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.12
FINRA.</font> <font style="font-family: Times New Roman; font-size: 13px">For a period of 90
days from the later of the Closing Date or the Option Closing Date
(if any), the Company shall advise the Representative (who shall
make an appropriate filing with FINRA) if it is or becomes aware
that (i) any officer or director of the Company, (ii) any
beneficial owner of 5% or more of any class of the Company's
securities or (iii) any beneficial owner of the Company's
unregistered equity securities which were acquired during the 180
days immediately preceding the filing of the Registration Statement
is or becomes an affiliate or associated person of a FINRA member
participating in the Offering (as determined in accordance with the
rules and regulations of FINRA).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.13
No Fiduciary Duties.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company
acknowledges and agrees that the Underwriters' responsibility to
the Company is solely contractual in nature and that none of the
Underwriters or their affiliates or any selling agent shall be
deemed to be acting in a fiduciary capacity, or otherwise owes any
fiduciary duty to the Company or any of its affiliates in
connection with the Offering and the other transactions
contemplated by this Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.14
Company Lock-Up Agreement.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company, on
behalf of itself and any successor entity, agrees that, without the
prior written consent of the Representative, it will not, during
the period commencing on the date hereof and ending thirty (30)
days from the date of this Agreement or such earlier date that the
Company announces the results of its Phase 3 clinical trials (the
<font style="font-weight: bold">&#x201C;Lock-Up
Period&#x201D;)</font>,<font style="font-weight: bold">&#xA0;</font>(i) offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or
indirectly, any shares of capital stock of the Company or any
securities convertible into or exercisable or exchangeable for
shares of capital stock of the Company; or (ii) file or cause to be
filed any registration statement with the Commission relating to
the offering of any shares of capital stock of the Company or any
securities convertible into or exercisable or exchangeable for
shares of capital stock of the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 10"><br>
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 84px">
<font style="font-family: Times New Roman; font-size: 13px">The
restrictions contained in this Section 3.14 shall not apply to (i)
the Securities to be sold hereunder, (ii) the issuance by the
Company of shares of Common Stock upon the exercise of a stock
option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement,
Disclosure Package and Prospectus,(iii) the issuance by the Company
of stock options under any equity compensation plan of the Company,
and (iv) the sale or issuance by the Company to a non-U.S. person,
as such term is defined in Regulation S promulgated under the
Securities Act, at a price per share that is equal to or more than
the per Firm Share public offering price.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.15
Release of D&amp;O Lock-up Period.</font> <font style="font-family: Times New Roman; font-size: 13px">If the
Representative, in its sole discretion, agrees to release or waive
the restrictions set forth in the Lock-Up Agreements described in
Section 2.27 hereof for an officer, director or shareholder of the
Company, the Representative shall provide the Company with notice
of the impending release or waiver at least three (3) Business Days
before the effective date of the release or waiver, the Company
agrees if required by applicable law to announce the impending
release or waiver by a press release substantially in the form of
<font style="text-decoration: underline">Exhibit B</font> hereto
through a major news service at least two (2) Business Days before
the effective date of the release or waiver.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.16
Blue Sky Qualifications.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
use its best efforts, in cooperation with the Underwriters, if
necessary, to qualify the Securities for offering and sale under
the applicable securities laws of such states and other
jurisdictions (domestic or foreign) as the Representative may
designate and to maintain such qualifications in effect so long as
required to complete the distribution of the Securities; provided,
however, that the Company shall not be obligated to file any
general consent to service of process or to qualify as a foreign
corporation or as a dealer in securities in any jurisdiction in
which it is not so qualified or to subject itself to taxation in
respect of doing business in any jurisdiction in which it is not
otherwise so subject.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.17
Reporting Requirements.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company, during
the period when a prospectus relating to the Securities is (or, but
for the exception afforded by Rule 172, would be) required to be
delivered under the Securities Act, will file all documents
required to be filed with the Commission pursuant to the Exchange
Act within the time periods required by the Exchange Act and
Exchange Act Regulations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.18
Press Releases.</font> <font style="font-family: Times New Roman; font-size: 13px">Prior to the
Closing Date and any Option Closing Date, the Company shall not
issue any press release or other communication directly or
indirectly or hold any press conference with respect to the
Company, its condition, financial or otherwise, or earnings,
business affairs or business prospects (except for routine oral
marketing communications in the ordinary course of business and
consistent with the past practices of the Company and of which the
Representative is notified), without the prior written consent of
the Representative, which consent shall not be unreasonably
withheld, unless in the judgment of the Company and its counsel,
and after notification to the Representative, such press release or
communication is required by law.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">3.19
Sarbanes-Oxley.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
at all times comply with all applicable provisions of the
Sarbanes-Oxley Act in effect from time to time.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CONDITIONS
OF UNDERWRITERS' OBLIGATIONS.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
obligations of the Underwriters to purchase and pay for the
Securities, as provided herein, shall be subject to (i) the
continuing accuracy of the representations and warranties of the
Company as of the date hereof and as of each of the Closing Date
and the Option Closing Date, if any; (ii) the accuracy of the
statements of officers of the Company made pursuant to the
provisions hereof; (iii) the performance by the Company of its
obligations hereunder; and (iv) the following
conditions:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.1
Regulatory Matters.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.1.1 Absence of Certain Commission
Actions; Required Filings</font>. <font style="font-family: Times New Roman; font-size: 13px">At each of the
Closing Date and any Option Closing Date, no stop order suspending
the effectiveness of the Registration Statement or any
post-effective amendment thereto shall have been issued under the
Securities Act, no order preventing or suspending the use of any
Preliminary Prospectus or the Prospectus shall have been issued and
no proceedings for any of those purposes shall have been instituted
or are pending or, to the Company's knowledge, contemplated by the
Commission. The Company has complied with each request (if any)
from the Commission for additional information. A prospectus
containing the Rule 430B Information shall have been filed with the
Commission in the manner and within the time frame required by Rule
424(b) under the Securities Act Regulations (without reliance on
Rule 424(b)(8)) or a post-effective amendment providing such
information shall have been filed with, and declared effective by,
the Commission in accordance with the requirements of Rule 430B
under the Securities Act Regulations.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.1.2 FINRA Clearance</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">On or before the
date of this Agreement, the Representative shall have received
clearance from FINRA as to the amount of compensation allowable or
payable to the Underwriters as described in the Registration
Statement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.1.3 NYSE American Stock Market
Clearance</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">On or before the
Closing Date, the Firm Shares, and on or before the Option Closing
Date, the Additional Shares, shall have been approved for listing
on the NYSE American.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-weight: bold;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
4.2&#xA0;</font> <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Company
Counsel Matters.</font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.2.1 Closing Date Opinion of Counsel
to the Company</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">On the Closing
Date, the Representative shall have received the favorable opinion
of Hart &amp; Hart, LLC and a written statement providing certain
&#x201C;10b-5&#x201D; negative assurances, dated the Closing Date and
addressed to the Representative, substantially in the form attached
hereto as <font style="text-decoration: underline">Exhibit
C.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.2.2 Option Closing Date Opinion of
Counsel</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">On the Option
Closing Date, if any, the Representative shall have received the
favorable opinion of counsel listed in Section 4.2.1, dated the
Option Closing Date, addressed to the Representative and in form
and substance reasonably satisfactory to the Representative,
confirming as of the Option Closing Date, the statements made by
such counsel in its opinion delivered on the Closing
Date.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.2.3 Reliance</font>.</font>
<font style="font-family: Times New Roman; font-size: 13px">In rendering such
opinions, such counsel may rely: (i) as to matters involving the
application of laws other than the laws of the United States and
jurisdictions in which they are admitted, to the extent such
counsel deems proper and to the extent specified in such opinion,
if at all, upon an opinion or opinions (in form and substance
reasonably satisfactory to the Representative) of other counsel
reasonably acceptable to the Representative, familiar with the
applicable laws; and (ii) as to matters of fact, to the extent they
deem proper, on certificates or other written statements of
officers of the Company and officers of departments of various
jurisdictions having custody of documents respecting the corporate
existence or good standing of the Company, provided that copies of
any such statements or certificates shall be delivered to
Representative Counsel if requested. The opinion referred to in
Sections 4.2.1 above and any related Option Closing Date opinion
shall include a statement to the effect that it may be relied upon
by Representative Counsel in its written statement providing
certain &#x201C;10b-5&#x201D; negative assurances delivered to the
Underwriters.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.3
Comfort Letters.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.3.1 Cold Comfort
Letter</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Within 12 hours
after the time this Agreement is executed the Representative shall
have received a cold comfort letter containing statements and
information of the type customarily included in accountants'
comfort letters with respect to the financial statements and
certain financial information contained in the Registration
Statement, the Disclosure Package and the Prospectus, addressed to
the Representative and in form and substance satisfactory in all
respects to you and to Representative Counsel from the Auditor,
dated such date.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">22</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.3.2 Bring-down Comfort
Letter</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">At each of the
Closing Date and the Option Closing Date, if any, the
Representative shall have received from the Auditor a letter, dated
as of the Closing Date or the Option Closing Date, as applicable,
to the effect that the Auditor reaffirms the statements made in the
letter furnished pursuant to Section 4.3.1, except that the
specified date referred to shall be a date not more than one (1)
business day prior to the Closing Date or the Option Closing Date,
as applicable.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.4
Officers' Certificates.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.4.1 Officers'
Certificate</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
have furnished to the Representative a certificate, dated the
Closing Date and any Option Closing Date (if such date is other
than the Closing Date), of its Chief Executive Officer and its
Chief Financial Officer or Chief Operating Officer stating that (i)
such officers have carefully examined the Registration Statement,
the Disclosure Package, any Issuer Free Writing Prospectus and the
Prospectus and, in their opinion, the Registration Statement and
each amendment thereto, as of the Applicable Time and as of the
date of this Agreement and as of the Closing Date (or any Option
Closing Date if such date is other than the Closing Date) did not
include any untrue statement of a material fact and did not omit to
state a material fact required to be stated therein or necessary to
make the statements therein not misleading, and the Disclosure
Package, as of the Applicable Time and as of the Closing Date (or
any Option Closing Date if such date is other than the Closing
Date), any Issuer Free Writing Prospectus as of its date and as of
the Closing Date (or any Option Closing Date if such date is other
than the Closing Date), the Prospectus and each amendment or
supplement thereto, as of the respective date thereof and as of the
Closing Date, did not include any untrue statement of a material
fact and did not omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances
in which they were made, not misleading, (ii) since the date of
this Agreement, no event has occurred which should have been set
forth in a supplement or amendment to the Registration Statement,
the Disclosure Package or the Prospectus, (iii) to the best of
their knowledge after reasonable investigation, as of the Closing
Date (or any Option Closing Date if such date is other than the
Closing Date), the representations and warranties of the Company in
this Agreement are true and correct in all material respects and
the Company has complied with all agreements and satisfied all
conditions on its part to be performed or satisfied hereunder at or
prior to the Closing Date (or any Option Closing Date if such date
is other than the Closing Date), and (iv) there has not been,
subsequent to the date of the most recent audited financial
statements included or incorporated by reference in the Disclosure
Package, any material adverse change in the financial position or
results of operations of the Company, or any change or development
that, singularly or in the aggregate, would involve a material
adverse change or a prospective material adverse change, in or
affecting the condition (financial or otherwise), results of
operations, business, assets or prospects of the Company, except as
set forth in the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">4.4.2 Secretary's
Certificate</font>.</font> <font style="color: #000000; font-family: Times New Roman; font-size: 13px">At
each of the Closing Date and the Option Closing Date, if any, the
Representative shall have received a certificate of the Company
signed by the Secretary or the Assistant Secretary of the Company,
dated the Closing Date or the Option Date, as the case may be,
respectively, certifying: (i) that each of the Charter and Bylaws
is true and complete, has not been modified and is in full force
and effect; (ii) that the resolutions of the Company's Board of
Directors and the Pricing Committee of the Board of Directors
relating to the Offering are in full force and effect and have not
been modified; (iii) as to the accuracy and completeness of all
correspondence between the Company or its counsel and the
Commission; and (iv) as to the incumbency of the officers of the
Company. The documents referred to in such certificate shall be
attached to such certificate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">23</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.5
No Material Changes.</font> <font style="font-family: Times New Roman; font-size: 13px">Prior to and on
each of the Closing Date and each Option Closing Date, if any: (i)
there shall have been no material adverse change or development
involving a prospective material adverse change in the condition or
prospects or the business activities, financial or otherwise, of
the Company from the latest dates as of which such condition is set
forth in the Registration Statement and no material change in the
capital stock or debt of the Company, the Disclosure Package and
the Prospectus; (ii) no action, suit or proceeding, at law or in
equity, shall have been pending or threatened against the Company
or, to the Company's knowledge, any Insider before or by any court
or federal or state commission, board or other administrative
agency wherein an unfavorable decision, ruling or finding may
materially adversely affect the business, operations, prospects or
financial condition or income of the Company, except as set forth
in the Registration Statement, the Disclosure Package and the
Prospectus; (iii) no stop order shall have been issued under the
Securities Act and no proceedings therefor shall have been
initiated or threatened by the Commission; (iv) no action shall
have been taken and no law, statute, rule, regulation or order
shall have been enacted, adopted or issued by any Governmental
Entity which would prevent the issuance or sale of the Securities
or materially and adversely affect or potentially materially and
adversely affect the business or operations of the Company; (v) no
injunction, restraining order or order of any other nature by any
federal or state court of competent jurisdiction shall have been
issued which would prevent the issuance or sale of the Securities
or materially and adversely affect or potentially materially and
adversely affect the business or operations of the Company and (vi)
the Registration Statement, the Disclosure Package and the
Prospectus and any amendments or supplements thereto shall contain
all material statements which are required to be stated therein in
accordance with the Securities Act and the Securities Act
Regulations and shall conform in all material respects to the
requirements of the Securities Act and the Securities Act
Regulations, and neither the Registration Statement, the Disclosure
Package, the Prospectus nor any Issuer Free Writing Prospectus nor
any amendment or supplement thereto shall contain any untrue
statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were
made, not misleading<font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.6
No Material Misstatement or Omission.</font> <font style="font-family: Times New Roman; font-size: 13px">The Underwriters
shall not have discovered and disclosed to the Company on or prior
to the Closing Date and any Option Closing Date that the
Registration Statement or any amendment or supplement thereto
contains an untrue statement of a fact which, in the opinion of
counsel for the Underwriters, is material or omits to state any
fact which, in the opinion of such counsel, is material and is
required to be stated therein or is necessary to make the
statements therein not misleading, or that the Registration
Statement, Disclosure Package, any Issuer Free Writing Prospectus
or the Prospectus or any amendment or supplement thereto contains
an untrue statement of fact which, in the opinion of such counsel,
is material or omits to state any fact which, in the opinion of
such counsel, is material and is necessary in order to make the
statements, in the light of the circumstances under which they were
made, not misleading.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.7
Corporate Proceedings.</font> <font style="font-family: Times New Roman; font-size: 13px">All corporate
proceedings and other legal matters incident to the authorization,
form and validity of each of this Agreement, the Securities, the
Registration Statement, the Disclosure Package, each Issuer Free
Writing Prospectus, if any, and the Prospectus and all other legal
matters relating to this Agreement and the transactions
contemplated hereby shall be reasonably satisfactory in all
material respects to counsel for the Underwriters, and the Company
shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such
matters.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.8
Delivery of Lock-Up Agreements.</font> <font style="font-family: Times New Roman; font-size: 13px">On or before the
date of this Agreement, the Company shall have delivered to the
Representative executed copies of the Lock-Up Agreements from each
of the persons listed in <font style="text-decoration: underline">Schedule 3</font> hereto.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.9
Good Standing Certificates.</font> <font style="font-family: Times New Roman; font-size: 13px">On the Closing Date
and the Option Closing Date, if any, the Company shall have
delivered to the Representative a certificate of good standing from
the State of Colorado for the Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">4.10
Additional Documents.</font> <font style="font-family: Times New Roman; font-size: 13px">At the Closing Date
and at each Option Closing Date (if any), Representative Counsel
shall have been furnished with such documents and opinions as they
may require for the purpose of enabling Representative Counsel to
deliver an opinion to the Underwriters, or in order to evidence the
accuracy of any of the representations or warranties, or the
fulfillment of any of the conditions, herein contained; and all
proceedings taken by the Company in connection with the issuance
and sale of the Securities as herein contemplated shall be
satisfactory in form and substance to the Representative and
Representative Counsel.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">24</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">5.&#xA0;</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">INDEMNIFICATION.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">5.1
General.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company shall
indemnify and hold harmless each Underwriter, its affiliates and
each of its and their respective directors, officers, members,
employees, representatives, partners, shareholders, affiliates,
counsel and agents and each person, if any, who controls any such
Underwriter within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act (collectively the
&#x201C;<font style="font-weight: bold">Underwriter Indemnified
Parties</font>,&#x201D; and each an &#x201C;<font style="font-weight: bold">Underwriter Indemnified Party</font>&#x201D;),
against any and all loss, liability, claim, damage and expense
whatsoever (including but not limited to any and all legal or other
expenses reasonably incurred in investigating, preparing or
defending against any litigation, commenced or threatened, or any
claim whatsoever, whether arising out of any action between any of
the Underwriter Indemnified Parties and the Company or between any
of the Underwriter Indemnified Parties and any third party, or
otherwise) to which they or any of them may become subject under
the Securities Act, the Exchange Act or any other statute or at
common law or otherwise or under the laws of foreign countries,
arising out of or based upon any untrue statement or alleged untrue
statement of a material fact contained in (i) the Registration
Statement, the Disclosure Package, the Preliminary Prospectus, the
Prospectus or any Issuer Free Writing Prospectus (as from time to
time each may be amended and supplemented); (ii) any materials or
information provided to investors by, or with the approval of, the
Company in connection with the marketing of the Offering, including
any &#x201C;road show&#x201D; or investor presentations made to
investors by the Company (whether in person or electronically); or
(iii) any application or other document or written communication
(in this Section 5, collectively called &#x201C;<font style="font-weight: bold">application</font>&#x201D;) executed by the
Company or based upon written information furnished by the Company
in any jurisdiction in order to qualify the Common Stock under the
securities laws thereof or filed with the Commission, any state
securities commission or agency, the Exchange or any other national
securities exchange; or the omission or alleged omission therefrom
of a material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances
under which they were made, not misleading, unless such statement
or omission was made in reliance upon, and in conformity with, the
Underwriters&#x2019; Information. With respect to any untrue
statement or omission or alleged untrue statement or omission made
in the Disclosure Package, the indemnity agreement contained in
this Section 5.1.1 shall not inure to the benefit of any
Underwriter Indemnified Party to the extent that any loss,
liability, claim, damage or expense of such Underwriter Indemnified
Party results from the fact that a copy of the Prospectus was not
given or sent to the person asserting any such loss, liability,
claim or damage at or prior to the written confirmation of sale of
the Common Stock to such person as required by the Securities Act
and the Securities Act Regulations, and if the untrue statement or
omission has been corrected in the Prospectus, unless such failure
to deliver the Prospectus was a result of non-compliance by the
Company with its obligations under Section 3.3 hereof.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">5.2
Procedure</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">If any action is
brought against an Underwriter Indemnified Party in respect of
which indemnity may be sought against the Company pursuant to
Section 5.1.1, such Underwriter Indemnified Party shall promptly
notify the Company in writing of the institution of such action and
the Company shall be entitled to participate therein and, to the
extent that it wishes, jointly with any other similarly notified
indemnifying party, to assume the defense of such action, including
the employment and fees of counsel (subject to the reasonable
approval of such Underwriter Indemnified Party) and payment of
actual expenses. Such Underwriter Indemnified Party shall have the
right to employ its or their own counsel in any such case, but the
fees and expenses of such counsel shall be at the expense of such
Underwriter Indemnified Party unless (i) the employment of such
counsel at the expense of the Company shall have been authorized in
writing by the Company in connection with the defense of such
action, or (ii) the Company shall not have employed counsel to have
charge of the defense of such action, or (iii) such indemnified
party or parties shall have been advised by its counsel that there
may be defenses available to it or them which are different from or
additional to those available to the Company (in which case the
Company shall not have the right to direct the defense of such
action on behalf of the indemnified party or parties), in any of
which events the reasonable fees and expenses of not more than one
additional firm of attorneys selected by the Underwriter
Indemnified Parties who are party to such action (in addition to
local counsel) shall be borne by the Company. Notwithstanding
anything to the contrary contained herein, if any Underwriter
Indemnified Party shall assume the defense of such action as
provided above, the Company shall have the right to approve the
terms of any settlement of such action, which approval shall not be
unreasonably withheld.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">5.3
Indemnification of the Company.</font> <font style="font-family: Times New Roman; font-size: 13px">Each Underwriter,
severally and not jointly, shall indemnify and hold harmless the
Company, its directors, its officers who signed the Registration
Statement and persons who control the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act
against any and all loss, liability, claim, damage and expense
described in the foregoing indemnity from the Company to the
several Underwriters, as incurred, but only with respect to such
losses, liabilities, claims, damages and expenses (or actions in
respect thereof) which arise out of or are based upon untrue
statements or omissions made in the Registration Statement, any
Preliminary Prospectus, the Disclosure Package or Prospectus or any
amendment or supplement thereto or in any application, in reliance
upon, and in strict conformity with, the Underwriters&#x2019;
Information. In case any action shall be brought against the
Company or any other person so indemnified based on any Preliminary
Prospectus, the Registration Statement, the Disclosure Package or
Prospectus or any amendment or supplement thereto or any
application, and in respect of which indemnity may be sought
against any Underwriter, such Underwriter shall have the rights and
duties given to the Company, and the Company and each other person
so indemnified shall have the rights and duties given to the
several Underwriters by the provisions of Section 5.1.2. The
Company agrees promptly to notify the Representative of the
commencement of any litigation or proceedings against the Company
or any of its officers, directors or any person, if any, who
controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, in connection
with the issuance and sale of the Common Stock or in connection
with the Registration Statement, the Disclosure Package, the
Prospectus or any Issuer Free Writing Prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">25</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">5.4
Contribution</font>.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">5.4.1 Contribution
Rights</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">If the
indemnification provided for in this Section 5 shall for any reason
be unavailable to or insufficient to hold harmless an indemnified
party under Section 5.1 or 5.2 in respect of any loss, claim,
damage or liability, or any action in respect thereof, referred to
therein, then each indemnifying party shall, in lieu of
indemnifying such indemnified party, contribute to the amount paid
or payable by such indemnified party as a result of such loss,
claim, damage or liability, or action in respect thereof, (i) in
such proportion as shall be appropriate to reflect the relative
benefits received by the Company, on the one hand, and each of the
Underwriters, on the other hand, from the Offering, or (ii) if the
allocation provided by clause (i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) above but also
the relative fault of the Company, on the one hand, and the
Underwriters, on the other, with respect to the statements or
omissions that resulted in such loss, claim, damage or liability,
or action in respect thereof, as well as any other relevant
equitable considerations. The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other, with
respect to such Offering shall be deemed to be in the same
proportion as the total proceeds from the Offering (before
deducting expenses) received by the Company bear to the total
underwriting discount and commissions received by the Underwriters
in connection with the Offering, in each case as set forth in the
table on the cover page of the Prospectus. The relative fault of
the Company, on the one hand, and the Underwriters, on the other,
shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to
information supplied by the Company, on the one hand, or the
Underwriters, on the other, the intent of the parties and their
relative knowledge, access to information and opportunity to
correct or prevent such untrue statement, omission, act or failure
to act; provided that the parties hereto agree that the written
information furnished to the Company through the Representative by
or on behalf of any Underwriter for use in any Preliminary
Prospectus, any Registration Statement or the Prospectus, or in any
amendment or supplement thereto, consists solely of the
Underwriters&#x2019; Information. The Company and the Underwriters
agree that it would not be just and equitable if contributions
pursuant to this Section 5.3.1 were to be determined by pro rata
allocation or by any other method of allocation that does not take
into account the equitable considerations referred to herein. The
amount paid or payable by an indemnified party as a result of the
loss, claim, damage, expense, liability, action, investigation or
proceeding referred to above in this Section 5.3.1 shall be deemed
to include, for purposes of this Section 5.3.1, any legal or other
expenses reasonably incurred by such indemnified party in
connection with investigating, preparing to defend or defending
against or appearing as a third party witness in respect of, or
otherwise incurred in connection with, any such loss, claim,
damage, expense, liability, action, investigation or proceeding.
Notwithstanding the provisions of this Section 5.3.1 no Underwriter
shall be required to contribute any amount in excess of the total
discount and commission received by such Underwriter in connection
with the Offering less the amount of any damages which such
Underwriter has otherwise paid or becomes liable to pay by reason
of any untrue or alleged untrue statement, omission or alleged
omission, act or alleged act or failure to act or alleged failure
to act. No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be
entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; text-indent: 84px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">5.4.2 Contribution
Procedure</font>.</font> <font style="font-family: Times New Roman; font-size: 13px">Within fifteen (15)
days after receipt by any party to this Agreement (or its
representative) of notice of the commencement of any action, suit
or proceeding, such party will, if a claim for contribution in
respect thereof is to be made against another party
(&#x201C;contributing party&#x201D;), notify the contributing party
of the commencement thereof, but the failure to so notify the
contributing party will not relieve it from any liability which it
may have to any other party other than for contribution hereunder.
In case any such action, suit or proceeding is brought against any
party, and such party notifies a contributing party or its
representative of the commencement thereof within the aforesaid 15
days, the contributing party will be entitled to participate
therein in the defense of any action, suit or proceeding with the
notifying party and any other contributing party similarly
notified. Any such contributing party shall not be liable to any
party seeking contribution on account of any settlement of any
claim, action or proceeding affected by such party seeking
contribution without the written consent of such contributing
party. The contribution provisions contained in this Section 5.3.2
are intended to supersede, to the extent permitted by law, any
right to contribution under the Securities Act, the Exchange Act or
otherwise available. The Underwriters&#x2019; obligations to
contribute as provided in this Section 5.3 are several and in
proportion to their respective underwriting obligation, and not
joint.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">26</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">6.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">DEFAULT
BY AN UNDERWRITER.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">6.1
Default Not Exceeding 10% of Firm Shares or Additional
Shares.</font> <font style="font-family: Times New Roman; font-size: 13px">If any Underwriter
or Underwriters shall default in its or their obligations to
purchase the Firm Shares or the Additional Shares, if the
Over-allotment Option is exercised hereunder, and if the number of
the Firm Shares or Additional Shares with respect to which such
default relates does not exceed in the aggregate 10% of the number
of Firm Shares or Additional Shares that all Underwriters have
agreed to purchase hereunder, then such Finn Shares or Additional
Shares to which the default relates shall be purchased by the
non-defaulting Underwriters in proportion to their respective
commitments hereunder.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">6.2
Default Exceeding 10% of Firm Shares or Additional Shares.</font>
<font style="font-family: Times New Roman; font-size: 13px">In the event that
the default addressed in Section 6.1 relates to more than 10% of
the Firm Shares or Additional Shares, the Underwriters may in their
discretion arrange for the Underwriters or for another party or
parties to purchase such Firm Shares or Additional Shares to which
such default relates on the terms contained herein. If, within one
(1) Business Day after such default relating to more than 10% of
the Firm Shares or Additional Shares, the Underwriters do not
arrange for the purchase of such Firm Shares or Additional Shares,
then the Company shall be entitled to a further period of one (1)
Business Day within which to procure another party or parties
satisfactory to the Underwriters to purchase said Firm Shares or
Additional Shares on such terms. In the event that neither the
Underwriters nor the Company arrange for the purchase of the Firm
Shares or Additional Shares to which a default relates as provided
in this Section 6, this Agreement will automatically be terminated
by the Underwriters or the Company without liability on the part of
the Company (except as provided in Sections 3.10 and 5 hereof) or
the several Underwriters (except as provided in Section 5 hereof);
provided, however, that if such default occurs with respect to the
Additional Shares, this Agreement will not terminate as to the Firm
Shares; and provided, further, that nothing herein shall relieve a
defaulting Underwriter of its liability, if any, to the other
Underwriters and to the Company for damages occasioned by its
default hereunder.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">6.3
Postponement of Closing Date.</font> <font style="font-family: Times New Roman; font-size: 13px">In the event that
the Firm Shares or Additional Shares to which the default relates
are to be purchased by the non-defaulting Underwriters, or are to
be purchased by another party or parties as aforesaid, the
Underwriters or the Company shall have the right to postpone the
Closing Date or Option Closing Date for a reasonable period, but
not in any event exceeding five (5) Business Days, in order to
effect whatever changes may thereby be made necessary in the
Registration Statement, the Disclosure Package or the Prospectus or
in any other documents and arrangements, and the Company agrees to
file promptly any amendment to the Registration Statement, the
Disclosure Package or the Prospectus that in the opinion of counsel
for the Underwriter may thereby be made necessary. The term
&#x201C;<font style="font-weight: bold">Underwriter</font>&#x201D;<font style="font-weight: bold">&#xA0;</font>as used in this Agreement shall
include any party substituted under this Section 6 with like effect
as if it had originally been a party to this Agreement with respect
to such Securities.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">7.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">RESERVED</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">EFFECTIVENESS
OF THIS AGREEMENT AND TERMINATION THEREOF.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.1
Effectiveness of the Agreement.</font> <font style="font-family: Times New Roman; font-size: 13px">This Agreement
shall become effective when both the Company and the Representative
have executed the same and delivered counterparts of such
signatures to the other party.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">27</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.2
Termination.</font> <font style="font-family: Times New Roman; font-size: 13px">The Representative
shall have the right to terminate this Agreement at any time prior
to any Closing Date, (i) if any domestic or international event or
act or occurrence has materially disrupted, or in the
Representative&#x2019;s opinion will in the immediate future
materially disrupt, general securities markets in the United
States; or (ii) if trading on the New York Stock Exchange or the
Nasdaq Stock Market LLC shall have been suspended or materially
limited, or minimum or maximum prices for trading shall have been
fixed, or maximum ranges for prices for securities shall have been
required by FINRA or by order of the Commission or any other
government authority having jurisdiction; or (iii) if the United
States shall have become involved in a new war or an increase in
major hostilities; or (iv) if a banking moratorium has been
declared by a New York State or federal authority; or (v) if a
moratorium on foreign exchange trading has been declared which
materially adversely impacts the United States securities markets;
or (vi) if the Company shall have sustained a material loss by
fire, flood, accident, hurricane, earthquake, theft, sabotage or
other calamity or malicious act which, whether or not such loss
shall have been insured, will, in the Representative&#x2019;s
opinion, make it inadvisable to proceed with the delivery of the
Firm Shares or Additional Shares; or (vii) if the Company is in
material breach of any of its representations, warranties or
covenants hereunder; or (viii) if the Representative shall have
become aware after the date hereof of such a material adverse
change in the conditions or prospects of the Company, or such
adverse material change in general market conditions as in the
Representative's judgment would make it impracticable to proceed
with the offering, sale and/or delivery of the Securities or to
enforce contracts made by the Underwriters for the sale of the
Securities.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.3
Expenses Upon Termination.</font> <font style="font-family: Times New Roman; font-size: 13px">Notwithstanding
anything to the contrary in this Agreement, except in the case of a
default by the Underwriters, pursuant to Section 6.2 above, in the
event that this Agreement shall not be carried out for any reason
whatsoever, within the time specified herein or any extensions
thereof pursuant to the terms herein, the Company shall be
obligated to pay to the Representative its actual and accountable
out-of-pocket expenses related to the transactions contemplated
herein then due and payable (including the fees and disbursements
of Representative Counsel) up to $25,000, and upon demand the
Company shall pay the full amount thereof to the Representative;
provided, however, that such expense cap in no way limits or
impairs the indemnification and contribution provisions of this
Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">8.4
Survival of Indemnification.</font> <font style="font-family: Times New Roman; font-size: 13px">Notwithstanding any
contrary provision contained in this Agreement, any election
hereunder or any termination of this Agreement, and whether or not
this Agreement is otherwise carried out, the provisions of Section
5 shall remain in full force and effect and shall not be in any way
affected by, such election or termination or failure to carry out
the terms of this Agreement or any part hereof.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">8.5 Representations</font>, <font style="font-weight: bold">Warranties</font>, <font style="font-weight: bold">Agreements to Survive.</font></font>
<font style="font-family: Times New Roman; font-size: 13px">All
representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company submitted
pursuant hereto, shall remain operative and in full force and
effect regardless of (i) any investigation made by or on behalf of
any Underwriter or its Affiliates or selling agents, any person
controlling any Underwriter, its officers or directors or any
person controlling the Company or (ii) delivery of and payment for
the Securities.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.</font>
<font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">MISCELLANEOUS.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.1
Notices.</font> <font style="font-family: Times New Roman; font-size: 13px">All communications
hereunder, except as herein otherwise specifically provided, shall
be in writing and shall be mailed (registered or certified mail,
return receipt requested), personally delivered or sent by
facsimile transmission and confirmed and shall be deemed given when
so delivered or faxed and confirmed or if mailed, two (2) days
after such mailing.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
to the Representative:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments,
LLC</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">590 Madison Avenue, 39</font><font style="font-size: 70%; vertical-align: top; color: #000000">th</font>
<font style="color: #000000">Floor</font></font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">New
York, New York 10022</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Attn:
Joseph T. Rallo</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">with
a copy (which shall not constitute notice) to:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 36px">
<font style="font-family: Times New Roman; font-size: 13px">Nelson
Mullins Riley &amp; Scarborough LLP</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 36px">
<font style="font-family: Times New Roman; font-size: 13px">101
Constitution Avenue NW, Suite 900</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 36px">
<font style="font-family: Times New Roman; font-size: 13px">Washington, DC
20001</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 36px">
<font style="font-family: Times New Roman; font-size: 13px">Attn:
Andrew M. Tucker, Esq.</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 36px">
<font style="font-family: Times New Roman; font-size: 13px">Fax
No.: (202) 689-2860</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">28</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
to the Company:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8229
Boone Blvd. #802</font></div>
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0; Vienna, VA
22182</font>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Attn:
Geert R. Kersten</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fax
No.: (703) 506-9471</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 84px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">with
a copy (which shall not constitute notice) to:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; Hart &amp; Hart,
LLC</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; 1624 Washington
Street</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; Denver, CO 80203</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; Attn: William T. Hart.
Esq.</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; Fax No.: (303)
839-5414</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.2
Headings.</font> <font style="font-family: Times New Roman; font-size: 13px">The headings
contained herein are for the sole purpose of convenience of
reference, and shall not in any way limit or affect the meaning or
interpretation of any of the terms or provisions of this
Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.3
Absence of Fiduciary Relationship.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company
acknowledges and agrees that:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">each Underwriter's
responsibility to the Company is solely contractual in nature, each
Underwriter has been retained solely to act as an underwriter in
connection with the Offering and no fiduciary, advisory or agency
relationship between the Company and the Underwriters has been
created in respect of any of the transactions contemplated by this
Agreement, irrespective of whether the Representative has advised
or is advising the Company on other matters;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">the price of the
Securities set forth in this Agreement was established by the
Company following discussions and arms-length negotiations with the
Representative, and the Company is capable of evaluating and
understanding, and understands and accepts, the terms, risks and
conditions of the transactions contemplated by this Agreement;
and</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 84px; text-indent: 156px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px">it has been advised
that the Underwriters and their respective affiliates are engaged
in a broad range of transactions which may involve interests that
differ from those of the Company and that the Underwriters have no
obligation to disclose such interests and transactions to the
Company by virtue of any fiduciary, advisory or agency
relationship.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.4
Research Analyst Independence.</font> <font style="font-family: Times New Roman; font-size: 13px">The Company
acknowledges that each Underwriter's research analysts and research
departments are required to be independent from its investment
banking division and are subject to certain regulations and
internal policies, and that such Underwriter's research analysts
may hold views and make statements or investment recommendations
and/or publish research reports with respect to the Company and/or
the offering that differ from the views of their investment banking
division. The Company acknowledges that each Underwriter is a full
service securities firm and as such from time to time, subject to
applicable securities laws, rules and regulations, may effect
transactions for its own account or the account of its customers
and hold long or short positions in debt or equity securities of
the Company; provided, however, that nothing in this Section 9.4
shall relieve the Underwriter of any responsibility or liability it
may otherwise bear in connection with activities in violation of
applicable securities laws, rules or regulations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.5
Amendment.</font> <font style="font-family: Times New Roman; font-size: 13px">This Agreement may
only be amended by a written instrument executed by each of the
parties <font style="color: #000000">hereto.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.6
Entire Agreement.</font> <font style="font-family: Times New Roman; font-size: 13px">This Agreement
(together with the other agreements and documents being delivered
pursuant to or in connection with this Agreement) constitutes the
entire agreement of the parties hereto with respect to the subject
matter hereof and thereof, and supersedes all prior agreements and
understandings of the parties, oral and written, with respect to
the subject matter hereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">29</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.7
Binding Effect.</font> <font style="font-family: Times New Roman; font-size: 13px">This Agreement
shall inure solely to the benefit of and shall be binding upon the
Representative, the Underwriters, the Company and the controlling
persons, directors and officers referred to in Section 5 hereof,
and their respective successors, legal representatives, heirs and
assigns, and no other person shall have or be construed to have any
legal or equitable right, remedy or claim under or in respect of or
by virtue of this Agreement or any provisions herein contained. The
term &#x201C;successors and assigns&#x201D; shall not include a
purchaser, in its capacity as such, of securities from any of the
Underwriters.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.8
Governing Law; Consent to Jurisdiction; Trial by Jury.</font>
<font style="font-family: Times New Roman; font-size: 13px">This Agreement
shall be governed by and construed and enforced in accordance with
the laws of the State of New York, without giving effect to
conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or
relating in any way to this Agreement shall be brought and enforced
in the New York Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York, and
irrevocably submits to such jurisdiction, which jurisdiction shall
be exclusive. The Company hereby waives any objection to such
exclusive jurisdiction and that such courts represent an
inconvenient forum. Any such process or summons to be served upon
the Company may be served by transmitting a copy thereof by
registered or certified mail, return receipt requested, postage
prepaid, addressed to it at the address set forth in Section 9.1
hereof. Such mailing shall be deemed personal service and shall be
legal and binding upon the Company in any action, proceeding or
claim. The Company agrees that the prevailing party(ies) in any
such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys' fees and expenses relating to such
action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent
permitted by applicable law, on behalf of its stockholders and
affiliates) and each of the Underwriters hereby irrevocably waives,
to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or
relating to this Agreement or the transactions contemplated
hereby.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">9.9
Execution in Counterparts.</font> <font style="font-family: Times New Roman; font-size: 13px">This Agreement may
be executed in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which shall be
deemed to be an original, but all of which taken together shall
constitute one and the same agreement, and shall become effective
when one or more counterparts has been signed by each of the
parties hereto and delivered to each of the other parties hereto.
Delivery of a signed counterpart of this Agreement by facsimile or
email/pdf transmission shall constitute valid and sufficient
delivery thereof.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font id="tab2" style="letter-spacing: 12px; color: black"></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">9.10 Waiver</font>, <font style="font-weight: bold">etc.</font></font> <font style="font-family: Times New Roman; font-size: 13px">The failure of any
of the parties hereto to at any time enforce any of the provisions
of this Agreement shall not be deemed or construed to be a waiver
of any such provision, nor to in any way effect the validity of
this Agreement or any provision hereof or the right of any of the
parties hereto to thereafter enforce each and every provision of
this Agreement. No waiver of any breach, non-compliance or
non-fulfillment of any of the provisions of this Agreement shall be
effective unless set forth in a written instrument executed by the
party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or
non-fulfillment shall be construed or deemed to be a waiver of any
other or subsequent breach, noncompliance or
non-fulfillment.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
[Signature Page Follows]</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">30</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 12px; margin-right: 7px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">If
the foregoing correctly sets forth the understanding between the
Underwriters and the Company, please so indicate in the space
provided below for that purpose, whereupon this letter shall
constitute a binding agreement between us.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Very
truly yours,</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">By:</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
/s/ Geert R. Kersten</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Name:</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Geert R. Kersten</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Title:</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Chief Executive Officer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 25px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Confirmed as of the date first written above, on
behalf of itself and as Representative of the several Underwriters
named on</font> <font style="text-decoration: underline; color: #000000">Schedule 1</font>
<font style="color: #000000">hereto:</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">KINGSWOOD
CAPITAL MARKETS,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">division
of Benchmark Investments, LLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:</font></div>
</td>
<td style="vertical-align: top; width: 45%; border-bottom: 2px solid #000000">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;/s/
Sam Fleischman</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Sam Fleischman</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Regulatory Principal</font></div>
</td>
<td style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
[Signature Page]</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Cel-Sci Corporation &#x2013; Underwriting Agreement</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">31</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SCHEDULE 1</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Underwriter</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Total
Number of</font> <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Firm
Shares to bePurchased</font> <font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Number
of Additional Option Shares to be Purchased if the Over-Allotment
Option is Fully Exercised</font> <font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Kingswood Capital
Markets, division of Benchmark Investments, LLC</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">1,395,000</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block;">210,000</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Westpark Capital,
Inc.<br></font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">5,000</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">0</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TOTAL</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,400,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">210,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">S-1</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SCHEDULE 2</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Pricing Information</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 432px"><font style="font-family: Times New Roman; font-size: 13px">Number of Firm
Shares:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="display: table-cell; width: 96px"><font style="font-family: Times New Roman; font-size: 13px">1,400,000&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 432px"><font style="font-family: Times New Roman; font-size: 13px">Number of
Additional
Shares:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">210,000</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 432px"><font style="font-family: Times New Roman; font-size: 13px">Public Offering
Price per
Share:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">22.62</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 432px"><font style="font-family: Times New Roman; font-size: 13px">Underwriting
Discount per
Share:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">1.5834</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 432px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">Proceeds to Company
per Share (before expenses):&#xA0;&#xA0;</font>
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">21.0366</font></div>
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="display: table">
<div style="display: table-row"><br></div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<br>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">S-2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SCHEDULE 2-B</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Issuer General Use Free Writing Prospectuses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Free Writing
Prospectus filed by the Company with the Commission on June 8,
2021.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">S-3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Filed pursuant to Rule&#xA0;433</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Registration Statement No.: 333-226558</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Issuer Free Writing Prospectus dated June 8, 2021</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Relating to Preliminary Prospectus Supplement dated June 8,
2021</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
TERM SHEET</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Public Offering of Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
This document does not provide full disclosure of all material
facts relating to the securities offered. Investors should read the
accompanying prospectus, any amendment and any applicable
prospectus supplement for disclosure of those facts, especially
risk factors relating to the securities offered, before making an
investment decision.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
A preliminary prospectus supplement to the accompanying prospectus
dated June 8, 2021 has been filed with the Securities and Exchange
Commission (SEC) in the United States and contains important
information relating to the securities described in this term
sheet. The issuer has filed a registration statement (including the
accompanying prospectus) with the SEC for the offering to which
this communication relates. Before you invest, you should read the
prospectus, as supplemented by the preliminary prospectus
supplement filed with the SEC, in that registration statement and
other documents the issuer has and will file with the SEC for more
complete information about the issuer and this offering. You may
get these documents for free by visiting EDGAR on the SEC website
at www.sec.gov. Alternatively, the issuer, any underwriter or any
dealer participating in the offering will arrange to send you the
prospectus, as supplemented, if you request it, from Kingswood
Capital Markets, Attention: Syndicate Desk, 590 Madison Avenue,
39th Floor, New York, New York 10022, by email at
syndicate@kingswoodcm.com, or by telephone at (212)
404-7002.</font><font style="color: #000000">&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Issuer:</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation (the &#x201C;<font style="font-weight: bold">Company</font>&#x201D;)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Number of Firm Shares:</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1,000,000
shares of common stock of the Company (each, a &#x201C;<font style="font-weight: bold">Share</font>&#x201D;).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Public price per Share:</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">$22.62</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Option to purchase additional Shares:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Underwriters (as defined below) will have an option, exercisable,
in whole or in part, in the sole discretion of the Underwriters, at
any time prior to the day that is the 30th day following the date
of the Underwriting Agreement, to purchase up to an additional
150,000 Shares on the same terms and conditions as set forth
herein.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Form&#xA0;of Underwriting:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Firm
commitment underwriting public offering by way of a prospectus
supplement to the Company&#x2019;s effective &#x201C;shelf&#x201D;
registration statement (File No.&#xA0;333-226558) (the
&#x201C;<font style="font-weight: bold">Offering</font>&#x201D;),
subject to a mutually acceptable underwriting agreement containing
the customary material adverse effect clauses.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Underwriter:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments, LLC is acting
as the book-running manager for the Offering (the
&#x201C;<font style="font-weight: bold">Underwriters</font>&#x201D;).</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Jurisdictions:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">No
action is being taken in any jurisdiction outside the United States
to permit a public offering of the Shares. None of the Shares in
this Offering will be offered or sold, directly or indirectly, nor
will any offering material or advertisements in connection with the
offer and sales of any of the Shares be distributed or published in
any jurisdiction, except under circumstances that will result in
compliance with the applicable rules&#xA0;and regulations of that
jurisdiction.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Underwriter&#x2019;s Fees:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company will pay the Underwriter a commission equal to 7.0% of the
gross proceeds of the Offering. The Company will reimburse the
Underwriter for certain expenses including $65,000 for actual fees
and expenses including legal fees, or $25,000 if the offering is
not consummated.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Use of Proceeds:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The net
proceeds of the Offering will be used to fund the continued
development of Multikine and LEAPS and for other general corporate
purposes.</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Listing:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Our
common stock is listed on the NYSE American under the symbol
&#x201C;CVM.&#x201D;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 40%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Closing Date:</font></div>
</td>
<td style="vertical-align: top; width: 3%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 57%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On or
about June 11, 2021 or such other date as the Company and the
Underwriter mutually agree.</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">S-4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SCHEDULE 3</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
List of Lock-Up Parties</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Geert
R. Kersten</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patricia
B. Prichep</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dr.
Eyal Talor</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dr.
Daniel H. Zimmerman</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">John
Cipriano</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dr.
Peter R. Young</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bruno
Baillavione</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Robert
Watson</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">S-5</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT A</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Lock-Up Agreement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
June 8, 2021</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments,
LLC</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">17
Battery Place, Suite 625</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">New
York, New York 10004</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Ladies
and Gentlemen:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
undersigned understands that Kingswood Capital Markets, division of
Benchmark Investments, LLC (the &#x201C;<font style="font-weight: bold">Representative</font>&#x201D;)<font style="font-weight: bold">&#xA0;</font>proposes to enter into an
Underwriting Agreement (the &#x201C;<font style="font-weight: bold">Underwriting Agreement</font>
&#x201C;)<font style="font-weight: bold">&#xA0;</font>with CEL-SCI
Corporation, a Colorado corporation (the &#x201C;<font style="font-weight: bold">Company</font>&#x201D;),<font style="font-weight: bold">&#xA0;</font>providing for the public offering
(the &#x201C;<font style="font-weight: bold">Public
Offering</font>&#x201D;)<font style="font-weight: bold">&#xA0;</font>of shares of common stock, par
value $0.01 per share, of the Company (the &#x201C;<font style="font-weight: bold">Shares</font>&#x201D;)<font style="font-weight: bold">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">To
induce the Representative to continue its efforts in connection
with the Public Offering, the undersigned hereby agrees that,
without the prior written consent of the Representative, the
undersigned will not, during the period commencing on the date
hereof and ending 30 days after the date of the final prospectus
(the &#x201C;<font style="font-weight: bold">Prospectus</font>&#x201D;) relating to the
Public Offering or such earlier date that the Company announces the
results of its Phase 3 clinical trials (the &#x201C;<font style="font-weight: bold">Lock-Up Period</font>&#x201D;), (1) offer,
pledge, sell, contract to sell, grant, lend, or otherwise transfer
or dispose of, directly or indirectly, any Shares or any securities
convertible into or exercisable or exchangeable for Shares, whether
now owned or hereafter acquired by the undersigned or with respect
to which the undersigned has or hereafter acquires the power of
disposition (collectively, the &#x201C;<font style="font-weight: bold">Lock-Up Securities</font>&#x201D;); (2) enter
into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of
the Lock-Up Securities, whether any such transaction described in
clause (1) above or this clause (2) is to be settled by delivery of
Lock-Up Securities, in cash or otherwise; (3) make any demand for
or exercise any right with respect to the registration of any
Lock-Up Securities; or (4) publicly disclose the intention to make
any offer, sale, pledge or disposition, or to enter into any
transaction, swap, hedge or other arrangement relating to any
Lock-Up Securities. Notwithstanding the foregoing, and subject to
the conditions below, the undersigned may transfer Lock-Up
Securities without the prior written consent of the Representative
in connection with (a) transactions relating to Lock-Up Securities
acquired in open market transactions after the completion of the
Public Offering;<font style="font-style: italic">&#xA0;</font><font style="text-decoration: underline">provided</font> that no filing under
Section&#xA0;13 or Section&#xA0;16(a) of the Securities Exchange
Act of 1934, as amended (the &#x201C;<font style="font-weight: bold">Exchange Act</font>&#x201D;), or other public
announcement shall be required or shall be voluntarily made during
the Lock-Up Period in connection with subsequent sales of Lock-Up
Securities acquired in such open market transactions pursuant to
this agreement; (b) transfers of Lock-Up Securities as a
<font style="font-style: italic">bona fide</font> gift, by will or
intestacy or to a family member or trust for the benefit of a
family member (for purposes of this lock-up agreement,
&#x201C;family member&#x201D; means any relationship by blood,
marriage or adoption, not more remote than first cousin); (c)
transfers of Lock-Up Securities to a charity or educational
institution; or (d) if the undersigned, directly or indirectly,
controls a corporation, partnership, limited liability company or
other business entity, any transfers of Lock-Up Securities to any
shareholder, partner or member of, or owner of similar equity
interests in, such corporation, partnership, limited liability
company or other business entity, as the case may be; <font style="text-decoration: underline">provided</font> that in the case of
any transfer pursuant to the foregoing clauses (b), (c) or (d), (i)
it shall be a condition to any such transfer that (i) the
transferee/donee agrees to be bound by the terms of this lock-up
agreement (including, without limitation, the restrictions set
forth in the preceding sentence) to the same extent as if the
transferee/donee were a party hereto; (ii) each party (donor,
donee, transferor or transferee) shall not be required by law
(including without limitation the disclosure requirements of the
Securities Act of 1933, as amended (the &#x201C;<font style="font-weight: bold">Securities Act</font>&#x201D;), and the Exchange
Act) to make, and shall agree to not voluntarily make, any filing
or public announcement of the transfer or disposition prior to the
expiration of the Lock-Up Period; and (iii) the undersigned
notifies the Representative at least two (2) business days prior to
the proposed transfer or disposition.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, the foregoing restrictions shall not apply to (i) the
exercise of stock options granted pursuant to the Company&#x2019;s
equity incentive plans, (ii) exercise of warrants, or (iii)
pursuant to an existing contract, instruction or plan (a
&#x201C;<font style="font-weight: bold">Plan</font>&#x201D;) that
satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B) under
the Exchange Act, (iv) the establishment of any new Plan (as such
may have been extended pursuant to the provisions
thereof).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">E-1</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
undersigned also agrees and consents to the entry of stop transfer
instructions with the Company&#x2019;s transfer agent and registrar
against the transfer of the undersigned&#x2019;s securities subject
to this this lock-up agreement except in compliance with this this
lock-up agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">If the
undersigned is an officer or director of the Company, (i) the
undersigned agrees that the foregoing restrictions shall be equally
applicable to any Shares that the undersigned may purchase in the
Public Offering; (ii) the Representative agrees that, at least
three (3) business days before the effective date of any release or
waiver of the foregoing restrictions in connection with a transfer
of Lock-Up Securities, the Representative will notify the Company
of the impending release or waiver; and (iii) the Company has
agreed in the Underwriting Agreement to announce the impending
release or waiver by press release through a major news service at
least two (2) business days before the effective date of the
release or waiver. Any release or waiver granted by the
Representative hereunder to any such officer or director shall only
be effective two (2) business days after the publication date of
such press release. The provisions of this paragraph will not apply
if (a) the release or waiver is effected solely to permit a
transfer of Lock-Up Securities not for consideration and (b) the
transferee has agreed in writing to be bound by the same terms
described in this lock-up agreement to the extent and for the
duration that such terms remain in effect at the time of such
transfer.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
undersigned understands that the Company and the Representative are
relying upon this lock-up agreement in proceeding toward
consummation of the Public Offering. The undersigned further
understands that this lock-up agreement is irrevocable and shall be
binding upon the undersigned&#x2019;s heirs, legal representatives,
successors and assigns.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
undersigned understands that, if the Underwriting Agreement does
not become effective, or if the Underwriting Agreement (other than
the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Shares to
be sold thereunder, the undersigned shall be released from all
obligations under this lock-up agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">This
lock-up agreement shall be governed by, and construed in accordance
with, the laws of the State of New York.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Very
truly yours,</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Name -
Please Print)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Signature)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Name
of Signatory, in the case of entities - Please Print)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: top; width: 51%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Title
of Signatory, in the case of entities - Please Print)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Address:</font></div>
</td>
<td style="vertical-align: top; width: 42%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 42%; border-bottom: 2px solid #000000">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">E-2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT B</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Press Release</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">CEL-SCI
Corporation</font><font style="color: #000000">,</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
[Date]</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 10px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">CEL-SCI Corporation, (the
&#x201C;</font><font style="font-weight: bold; color: #000000">Company</font><font style="color: #000000">&#x201D;)</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">announced today that Kingswood Capital Markets,
Inc., division of Benchmark Investments, LLC, acting as
representative for the underwriters in the Company's recent public
offering of the Company's common stock, is [waiving] [releasing] a
lock-up restriction with respect to</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 72px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">shares
of the Company's common stock held by [certain officers or
directors] [an officer or director] of the Company.
The</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table; margin-left: 13px">
<div style="display: table-row">
<div style="display: table-cell; width: 299px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">[waiver] [release] will take effect
on</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="display: table-cell; width: 72px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">,
20</font>&#xA0;&#xA0;&#xA0;&#xA0;<br></font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">and
the shares may be sold on or after such date.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 14px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">This
press release is not an offer or sale of the securities in the
United States or in any other jurisdiction where such offer or sale
is prohibited, and such securities may not be offered or sold in
the United States absent registration or an exemption from
registration under the Securities Act of 1933, as
amended.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 14px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 14px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 14px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">E-3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT C</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Opinion of Company Counsel</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company has been duly organized and is validly existing as a
corporation and is in good standing under the laws of the State of
Colorado with the requisite corporate power and authority to own or
lease, as the case may be, and operate its properties, and to
conduct its business, as described in the Registration Statement,
the Disclosure Package and the Prospectus and to enter into and
perform its obligations under the Underwriting
Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">()</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
authorized and outstanding shares of capital stock of the Company
is as set forth in the Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Firm/Additional Shares have been duly authorized for issuance and
sale to the Underwriters pursuant to the Underwriting Agreement
and, when issued and paid for pursuant to the terms of the
Underwriting Agreement, will be validly issued and fully paid and
non-assessable; the holders thereof are not and will not be subject
to personal liability solely by reason of being such holders. The
issuance of the Firm/Additional Shares is not and will not be
subject to the preemptive or similar rights of any holders of any
security of the Company arising by operation of law or under the
Company's Certificate of Incorporation, as amended (the
&#x201C;Charter&#x201D;), bylaws, as amended (the
&#x201C;Bylaws&#x201D;) or the Material Contracts ( as defined
below).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Underwriting Agreement has been duly and validly authorized,
executed and delivered by the Company and constitutes the valid and
legally binding obligation of the Company, enforceable against the
Company in accordance with its terms, except (a) as such
enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors' rights
generally, (b) as enforceability of any indemnification or
contribution provisions may be limited under the Federal and state
securities laws, and (c) that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before
which any proceeding therefore may be brought..</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(iii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
execution, delivery and performance of the Underwriting Agreement
and compliance by the Company with the terms and provisions thereof
and the consummation of the transactions contemplated thereby, and
the issuance and sale of the Securities, do not and will not,
whether with or without the giving of notice or the lapse of time
or both, (a) violate, conflict with, or result in a breach of, any
of the terms or provisions of, or constitute a default under, or
result in the creation or modification of any lien, security
interest, charge or encumbrance upon any of the properties or
assets of the Company pursuant to the terms of, any mortgage, deed
of trust, note, indenture, loan, contract, commitment or other
agreement or instrument filed or incorporated by reference as an
exhibit to the Registration Statement (collectively, the
&#x201C;Material Contracts&#x201D;), (b) result in any violation of
the provisions of the Charter, the By-laws or any other governing
documents of the Company, or (c) violate any law, statute or any
judgment, order or decree, rule or regulation applicable to the
Company of any Governmental Entity.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(vi)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
shares of Common Stock offered pursuant to the Prospectus conform
in all material respects to the description thereof contained in
the Registration Statement, the Disclosure Package and the
Prospectus. No United States or state statute or regulation
required to be described in the Prospectus is not described as
required (except as to the &#x201C;blue sky&#x201D; laws of the
various states, as to which such counsel expresses no opinions),
nor to such counsel's knowledge are any contracts or documents of a
character required to be described in the Registration Statement,
Disclosure Package or the Prospectus or to be filed or incorporated
by reference as exhibits to the Registration Statement not so
described or filed as required.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(vii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
statements in the Registration Statement, Disclosure Package and
the Prospectus under the heading &#x201C;Description of
Securities,&#x201D; insofar as such statements purport to summarize
legal matters, legal conclusions, the Charter, the Bylaws, or other
agreements or documents discussed therein, are correct in all
material respects.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(viii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Registration Statement has been declared effective by the
Commission under the Securities Act and the Securities Act
Regulations. No stop order suspending the effectiveness of the
Registration Statement has been issued under the Securities Act or
any order preventing or suspending the use of any Preliminary
Prospectus, any Issuer Free Writing Prospectus or the Prospectus
has been issued, and no proceedings for any such purpose have been
instituted or, to such counsel's knowledge, are pending by the
Commission or any other Governmental Entity. Any required filing of
the Prospectus, and any required supplement thereto, pursuant to
Rule 424(b) under the Securities Act Regulations, has been made in
the manner and within the time period required by Rule 424(b)
(without reference to Rule 424(b)(8)).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">E-4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(ix)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company is not required and, after giving effect to the Offering
and sale of the Firm/Additional Shares and the application of the
proceeds thereof as described in the Registration Statement, the
Disclosure Package and the Prospectus, will not be required, to
register as an &#x201C;investment company,&#x201D; under the
Investment Company Act of 1940, as amended.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(x)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">No
filing with, or authorization, approval, consent, license, order,
registration, qualification or decree of, any Governmental Entity
(other than under the Securities Act and the Securities Act
Regulations or with NYSE American, which have been obtained, or as
may be required under the securities or blue sky laws of the
various states, as to which we need express no opinion) is
necessary or required for the performance by the Company of its
obligations under the Underwriting Agreement, in connection with
the offering, issuance or sale of the Firm/Additional Shares
thereunder or the consummation of the transactions contemplated
thereby, except such as have been already made or obtained or as
may be required under the rules of the Exchange, state securities
laws or the rules of FINRA.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(xi)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Securities have been approved for listing on the Exchange upon
official notice of issuance.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(xii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
such counsel's knowledge, there are no persons with registration
rights or other similar rights to have any securities registered
pursuant to the Registrant Statement or otherwise registered for
sale by the Company under the Securities Act, except as disclosed
in the Registration Statement, the Disclosure Package and the
Prospectus.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(xiii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
such counsel's knowledge, there are not any pending legal
proceedings to which the Company or any of its Subsidiaries is a
party or of which the property of the Company or any of its
Subsidiaries is the subject which are required to be disclosed in
the Registration Statement, Disclosure Package and the Prospectus
and are not so disclosed.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(xiv)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Each
of (1) the Registration Statement, as of the time it became
effective, (2) the Disclosure Package, as of the Applicable Time,
and (3) the Prospectus, as of its date (in each case other than the
financial statements and supporting schedules included therein, as
to which no opinion need be rendered), complied as to form in all
material respects with the requirements of the Securities Act and
Securities Act Regulations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
opinion shall further include the following:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 7px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Nothing
has come to such counsel's attention that caused such counsel to
believe that (1) the Registration Statement, as of the time it
became effective, contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein
or necessary to make the statements therein not misleading; (2) the
Disclosure Package, as of the Applicable Time, contained an untrue
statement of a material fact or omitted to state a material fact
necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; or
(3) the Prospectus, as of its date and as of the Closing Date or
Option Closing Date, as applicable, contained or contains an untrue
statement of a material fact or omitted or omits to state a
material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not
misleading (except that, in each case, such counsel need express no
view, and make no statement, with respect to the financial
statements and schedules and notes thereto and other financial data
derived therefrom that are contained in or omitted from the
Registration Statement, the Disclosure Package or the
Prospectus).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">E-5</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>celsci_ex5.htm
<DESCRIPTION>OPINION OF HART & HART, LLC
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>celsci_ex5</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 5</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">HART
&amp; HART, LLC</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">ATTORNEYS
AT LAW</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1624
Washington Street</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Denver,
CO 80203</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">________</font>&#xA0;&#xA0;harttrinen@aol.com</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">(303) 839-0061</font>&#xA0;&#xA0;Fax: (303)
839-5414</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">June 8,
2021</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 4px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Blvd. #802</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 4px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vienna,
VA 22182</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">This
letter will constitute our opinion upon the legality of the sale by
CEL-SCI Corporation, a Colorado corporation
(&#x201C;CEL-SCI&#x201D;), of up to 1,400,000 shares of common stock,
all as referred to in the Registration Statement on Form S-3 (File
No. 333-226558) (the "Registration Statement") filed with the
Securities and Exchange Commission, declared effective by the
Securities and Exchange Commission (the &#x201C;Commission&#x201D;)
on August 24, 2018, the prospectus included therein (the
&#x201C;Prospectus&#x201D;) and the prospectus supplement, dated June
8, 2021 (the &#x201C;Prospectus Supplement&#x201D;). The Prospectus
Supplement pertains to an underwritten offering pursuant to an
Amended and Restated Underwriting Agreement dated June 8, 2021
between the Company and Kingswood Capital Markets, division of
Benchmark Investors, LLC. as Representative of the Several
Underwriters.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have examined the Articles of Incorporation, the Bylaws and the
minutes of the Board of Directors of CEL-SCI, the applicable laws
of the State of Colorado, and a copy of the Registration Statement,
the Prospectus and the Prospectus Supplement. In our opinion, the
shares of common stock mentioned above have been duly authorized,
and, when sold in the manner described in the Registration
Statement, the Prospectus and the Prospectus Supplement, will be
legally and validly issued, fully paid and non-assessable shares of
CEL-SCI&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 276px">
<font style="font-family: Times New Roman; font-size: 13px">Very
truly yours,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 276px">
<font style="font-family: Times New Roman; font-size: 13px">HART
&amp; HART, LLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 276px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 276px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-family: Times New Roman; font-size: 13px">HART &amp; HART,
LLC</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><br></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">William T.
Hart</font></font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">William T.
Hart</font></font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 276px"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">&#xA0;</font>&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 276px"></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>celsci_ex23.htm
<DESCRIPTION>CONSENT OF HART & HART, LLC
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>celsci_ex23</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 23</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CONSENT OF ATTORNEYS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Reference is made
to the Registration Statement of CEL-SCI Corporation (File
#333-226558), whereby the Company proposes to sell shares of its
common stock. Reference is also made to Exhibit 5 included as part
of this 8-K report relating to the validity of the securities
proposed to be sold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 72px">
<font style="font-family: Times New Roman; font-size: 13px">We
hereby consent to the use of our opinion concerning the validity of
the securities proposed to be issued and sold.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 300px">
<font style="font-family: Times New Roman; font-size: 13px">Very
truly yours,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 300px">
<font style="font-family: Times New Roman; font-size: 13px">HART
&amp; HART, LLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 300px">
<font style="font-family: Times New Roman; font-size: 13px">/s/
<font style="font-style: italic">William T.
Hart</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Denver,
Colorado</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">June 8,
2021</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>celsci_ex991.htm
<DESCRIPTION>PRESS RELEASE DATED JUNE 8, 2021
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>celsci_ex991</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 99.1</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 32px">
<font style="color: #7F7F7F">N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="celsci_ex991000.jpg">
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">8229 Boone
Boulevard, Suite 802&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Vienna, VA 22182.
USA</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Gavin de
Windt</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Telephone (703)
506-9460&#xA0;&#xA0;</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">www.cel-sci.com&#xA0;&#xA0;</font></font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font>&#xA0;</font></div>
</div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 16px">
CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, June 8, 2021 --</font> CEL-SCI Corporation <font style="font-weight: bold">(NYSE American: CVM), a Phase 3 cancer
immunotherapy company,</font> today announced that it has entered
into an underwriting agreement with Kingswood Capital Markets,
division of Benchmark Investments, Inc. under which the underwriter
has agreed to purchase on a firm commitment basis a minimum of
1,000,000 shares of common stock of the Company, at a price to the
public of $22.62 per share (the &#x201C;Public Price&#x201D;),
representing a 5% discount to the Company&#x2019;s June 8, 2021
closing share price. The closing of the offering is expected to
occur on or about June 11, 2021, subject to customary closing
conditions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments, LLC is acting
as sole book-running manager for the offering.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company also has granted to the underwriter a 30-day option to
purchase up to 15% of the offering at the Public Price. The use of
proceeds will be to fund the continued development of Multikine*,
LEAPS and for other general corporate purposes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
shares of common stock described above are being offered by CEL-SCI
pursuant to a "shelf" registration statement on Form S-3 (File No.
333-226558) filed with the Securities and Exchange Commission (SEC)
and the accompanying prospectus contained therein. The offering of
the shares of common stock is being made only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective registration statement. A preliminary prospectus
supplement and the accompanying prospectus relating to and
describing the terms of the offering has been filed with the SEC.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained
on the SEC's website at <font style="text-decoration: underline; color: #0000FF">http://www.sec.gov</font>
or by contacting Kingswood Capital Markets, Attention: Syndicate
Desk, 590 Madison Avenue, 39<font style="font-size: 70%; vertical-align: top">th</font> Floor, New York, NY
10022, by email at <font style="text-decoration: underline; color: #0000FF">syndicate@kingswoodcm.com</font>,
or by telephone at (212) 404-7002.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company&#x2019;s lead investigational
therapy Multikine is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the FDA.</font> The Company has operations
in Vienna, Virginia, and near Baltimore, Maryland.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, including the
risk that the offering is subject to market and other conditions
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the offering.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI&#x2019;s filings with the Securities and Exchange
Commission, including but not limited to its amended report on Form
10-K for the year ended September 30, 2020. The Company undertakes
no obligation to publicly release the result of any revision to
these forward-looking statements which may be made to reflect the
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>celsci_ex992.htm
<DESCRIPTION>PRESS RELEASE DATED JUNE 8, 2021
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2021 Issuer Direct Corporation -->
<title>celsci_ex992</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
EXHIBIT 99.2</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 32px">
<font style="color: #7F7F7F">N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="celsci_ex991000.jpg">
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">8229 Boone
Boulevard, Suite 802&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Vienna, VA 22182.
USA</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Gavin de
Windt</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Telephone (703)
506-9460&#xA0;&#xA0;</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">www.cel-sci.com&#xA0;&#xA0;</font></font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div style="text-align: right"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font>&#xA0;</font></div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 16px">
CEL-SCI INCREASES PREVIOUSLY ANNOUNCED</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 16px">
BOUGHT DEAL TO $31.7 MILLION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, June 8, 2021 --</font> CEL-SCI Corporation <font style="font-weight: bold">(NYSE American: CVM</font>), a Phase 3 cancer
immunotherapy company,<font style="font-weight: bold">&#xA0;</font>today announced that, due to
demand,<font style="font-family: Times New Roman">&#xA0;</font>the
underwriter has agreed to increase the size of its previously
announced offering and purchase on a firm commitment basis
1,400,000 shares of common stock of the Company, at a price to the
public of $22.62 per share (the &#x201C;Public Price&#x201D;),
representing a 5% discount to the closing price per share. The
closing of the offering is expected to occur on or about June 11,
2021, subject to customary closing conditions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Kingswood
Capital Markets, division of Benchmark Investments, LLC is acting
as sole book-running manager for the offering.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company also has granted to the underwriters a 30-day option to
purchase up to 15% of the offering at the Public Price. The use of
proceeds will be to fund the continued development of Multikine*,
LEAPS and for other general corporate purposes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the increase to the size of its previously
announced deal, the Company entered into an amended and restated
underwriting agreement with Kingswood Capital Markets, division of
Benchmark Investments, LLC for 1,400,000 shares of common stock of
the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
shares of common stock described above are being offered by CEL-SCI
pursuant to a "shelf" registration statement on Form S-3 (File No.
333-226558) filed with the Securities and Exchange Commission (SEC)
and the accompanying prospectus contained therein. The offering of
the shares of common stock is being made only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective registration statement. A preliminary prospectus
supplement and the accompanying prospectus relating to and
describing the terms of the offering has been filed with the SEC.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained
on the SEC's website at <font style="color: #000000">http://www.sec.gov</font> or by contacting
Kingswood Capital Markets, Attention: Syndicate Desk, 590 Madison
Avenue, 39<font style="font-size: 70%; vertical-align: top">th</font> Floor, New York, NY
10022, by email at <font style="color: #04BDE6">syndicate@kingswoodcm.com</font>, or by telephone
at (212) 404-7002.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company&#x2019;s lead investigational
therapy Multikine is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the FDA.</font> The Company has operations
in Vienna, Virginia, and near Baltimore, Maryland.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, including the
risk that the offering is subject to market and other conditions
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the offering.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI&#x2019;s filings with the Securities and Exchange
Commission, including but not limited to its report on Form 10-K
for the year ended September 30, 2020. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>celsci_ex991000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 celsci_ex991000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G -L# 2(  A$! Q$!_\0
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M>.[@BG06S,%D4,,[EYYKTW_A']'_ .@59_\ ?A?\*\X^&/\ R,=Q_P!>K?\
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M9]BA=S'); ZGWI]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cvm-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Issuer Direct Blueprint 2.0-->
<!--Based on XBRL 2.1-->
<!--Created on:6/9/21 6:36:33 PM-->
<schema targetNamespace="http://www.cel-sci.com/20211231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:cvm="http://www.cel-sci.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:enum="http://xbrl.org/2014/extensible-enumerations" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/2001/XMLSchema">
	<annotation>
		<appinfo>
			<link:roleType roleURI="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" id="Document-DocumentandEntityInformation">
				<link:definition>1001001 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
			</link:roleType>
			<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
			<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
		</appinfo>
	</annotation>
	<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
	<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
	<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
	<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
	<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
	<xs:element name="DocumentAndEntityInformationAbstract" id="cvm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cvm-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Issuer Direct Blueprint 2.0-->
<!--Based on XBRL 2.1-->
<!--Created on:6/9/21 6:36:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<link:roleRef roleURI="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" xlink:href="cvm-20211231.xsd#Document-DocumentandEntityInformation" xlink:type="simple" />
	<link:calculationLink xlink:type="extended" xlink:role="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cvm-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Issuer Direct Blueprint 2.0-->
<!--Based on XBRL 2.1-->
<!--Created on:6/9/21 6:36:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
	<link:roleRef roleURI="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" xlink:href="cvm-20211231.xsd#Document-DocumentandEntityInformation" xlink:type="simple" />
	<link:definitionLink xlink:type="extended" xlink:role="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cvm-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Issuer Direct Blueprint 2.0-->
<!--Based on XBRL 2.1-->
<!--Created on:6/9/21 6:36:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
	<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DocumentAndEntityInformationAbstract" xlink:label="loc_cvm_DocumentAndEntityInformationAbstract" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="cvm_DocumentAndEntityInformationAbstract_1_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DocumentAndEntityInformationAbstract_1_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="cvm_DocumentAndEntityInformationAbstract_2_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvm_DocumentAndEntityInformationAbstract_2_lbl" xml:lang="en-US">Document And Entity Information Abstract</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
		<link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
		<link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cvm-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Issuer Direct Blueprint 2.0-->
<!--Based on XBRL 2.1-->
<!--Created on:6/9/21 6:36:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<link:roleRef roleURI="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation" xlink:href="cvm-20211231.xsd#Document-DocumentandEntityInformation" xlink:type="simple" />
	<link:presentationLink xlink:type="extended" xlink:role="http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation">
		<link:loc xlink:type="locator" xlink:href="cvm-20211231.xsd#cvm_DocumentAndEntityInformationAbstract" xlink:label="loc_cvm_DocumentAndEntityInformationAbstract" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityCentralIndexKey" order="-115" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_AmendmentFlag" order="-112" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_AmendmentDescription" order="-111" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_DocumentType" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_DocumentPeriodEndDate" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityRegistrantName" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityIncorporationStateCountryCode" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityFileNumber" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityTaxIdentificationNumber" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityAddressAddressLine1" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityAddressAddressLine2" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityAddressCityOrTown" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityAddressStateOrProvince" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityAddressPostalZipCode" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_CityAreaCode" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_LocalPhoneNumber" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_WrittenCommunications" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_SolicitingMaterial" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_PreCommencementTenderOffer" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_PreCommencementIssuerTenderOffer" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_Security12bTitle" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_TradingSymbol" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_SecurityExchangeName" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvm_DocumentAndEntityInformationAbstract" xlink:to="loc_dei_EntityEmergingGrowthCompany" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
		<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>cvm-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20211231.xsd" xlink:type="simple"/>
    <context id="From-2021-06-08to2021-06-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="From-2021-06-08to2021-06-08"
      id="id6xP9DaUQwCNkM">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="From-2021-06-08to2021-06-08"
      id="id6xP9DaUQwCNkK">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="From-2021-06-08to2021-06-08"
      id="idec6a66480ee9494bb78b4fde1e2adb8c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="From-2021-06-08to2021-06-08"
      id="id76fdf93504ce4e5e89846bab44519683">2021-06-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="From-2021-06-08to2021-06-08"
      id="id550887ae360d4871804844d34f0a5456">CEL SCI CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="From-2021-06-08to2021-06-08"
      id="idf036194ab4d74c2780b1339a74ece17f">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="From-2021-06-08to2021-06-08"
      id="id602659a9c3ff4c479d1fb017745bebe2">001-11889</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="From-2021-06-08to2021-06-08"
      id="idcc2be5cf16fd4c9aa2359de1dd73eeb1">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="From-2021-06-08to2021-06-08"
      id="idc255ddcb33774a289764c5ed23496f54"> 8229 Boone Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From-2021-06-08to2021-06-08"
      id="id441b2f3a6e6e42d5a8037d7a2e40f499">#802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From-2021-06-08to2021-06-08"
      id="id1c36cc9261704e4db87c879fdbd0a59b">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From-2021-06-08to2021-06-08"
      id="idf665df6213a741d28d9ce378cd5b8a7c">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From-2021-06-08to2021-06-08"
      id="id96f0665e12514009aea88d0a8ea2bc02">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From-2021-06-08to2021-06-08"
      id="id820ea57840c9474280a6a3e2c580088f">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From-2021-06-08to2021-06-08"
      id="id569c86b4538f491eb6b8a1a822102835">506-9460</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="From-2021-06-08to2021-06-08"
      id="id29749334e81644a09d472b54db33804e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="From-2021-06-08to2021-06-08"
      id="idf6fea039f654405da59d8a266335231c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="From-2021-06-08to2021-06-08"
      id="id797ee6e52ced4480982f566616f0f1f3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="From-2021-06-08to2021-06-08"
      id="id3d77b48cf527403c82f7cebac8392029">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From-2021-06-08to2021-06-08"
      id="ida591fd9dabe14e6680ad29dccb1e1835"> Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From-2021-06-08to2021-06-08"
      id="idbcfc16aaaf7142758160b9a0f0c4d688"> CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From-2021-06-08to2021-06-08"
      id="id8433432dc6c34d05a0ad5bebc389e395">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="From-2021-06-08to2021-06-08"
      id="id9254cc13d2204843b6b7d740a7b7aa0d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151421135080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  08,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL SCI
CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">
84-0916344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">
8229 Boone Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vienna<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">
Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">
CVM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M(8')4J(5HB_N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ (8')4IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  A@<E21E3E
M]4H$   K$0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ (8')4I^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cvm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cvm-20211231.htm">cvm-20211231.htm</File>
    <File>celsci_ex11.htm</File>
    <File>celsci_ex23.htm</File>
    <File>celsci_ex5.htm</File>
    <File>celsci_ex991.htm</File>
    <File>celsci_ex992.htm</File>
    <File>cvm-20211231.xsd</File>
    <File>cvm-20211231_lab.xml</File>
    <File>cvm-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvm-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cvm-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20211231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20211231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cvm-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cvm",
   "nsuri": "http://www.cel-sci.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvm-20211231.htm",
      "contextRef": "From-2021-06-08to2021-06-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001001 - Document - Document and Entity Information",
     "role": "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvm-20211231.htm",
      "contextRef": "From-2021-06-08to2021-06-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "cvm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document And Entity Information Abstract",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cel-sci.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cel-sci.com/20211231/role/Document-DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001654954-21-006720-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-21-006720-xbrl.zip
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M^'E9@# VT;N\R%;1OR?SQ5/0@TD]J>IJ>7D5O7KU-H:)G\"SRJ;-VR4==8U
MO_X[K,3?D^8*)M9BZ.GYL^@4[H>3Z& X6@"/699@9IBP#\T931KGKR]@VT%3
M5AB[F%<M>N@PSUDR;7+8[PR_P1_,T(6OJS*?PH4 )E,S!UL&QG>X;L&BC>N%
MP2I:,-*LT56UK.E/J03M4A&=:)WDJ$&#$8N!F,*SHJ)JHN?PO-ML$SW%NE!?
MO$*E8[Y)I7[JP74G5Y3=>'3[897C:!<<M_XFKS.1%+@ ,03Z(DO)RCUHP B
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MPAQ,N%XR%+"8&R+N]J(?VF_.4-"5JRF*X<R!S9$$Z0('8<3D[I9I@VAMUD
M$G>9Q''TDJTPM_G#.::^7*45_ _N3S4%NZ(3O>:]9?1&N.L<U[[)9=&;0-68
M_3H>CW[!663^?EM_]GM99PI1UAQE7,##I=)E<"9QM Z9LA'W&$!3W!9,JWD8
MA\7CZ@$J/0D:W!1YFIY9,0LW'7*<>#[+,Q.LEF7\LHR /Z@Q]C#,]K#L:-+V
M7]P<ZV7 !J1W* \VH#8H=8SYL.C3TV'.B!A.APV[[>C%F@39>#2<(8N&$F3A
MHPX-%EQS9/T%.:"E6I,H \EZ_VQMYJNKWM\/O<!<>W?)@)ELRGAT]PQ8U$V
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MY81K4K5V<$Q&^OW#1SV8S]8JSC[.Z3,WZ?>V; UQ6&WR :RTLB)N<L*]<YN
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M&UQ(R#+@2-E^;R..JC*<(1>TPL-(!_JETV0H*&-*LNX2OEPSL"Y&-NY>J>@
MLXUH2"Q\%#C6!##=[R8Z+)_NMG'S,2%-ZX ]BWE'S+"B2%!W<RQM0,ZIBJ&P
M,'.NB6NX#3/LDJ6F8I NY86X6S:546;U-&^TI!C6:]DBX)2RDOQ8F*MVON7M
M@&6^QJ;JA +W,Q0[FO-U./LB=[EA;%G'O;VI?E9P([)E\"I:_1EEZ^JZNH$'
MP*@SL"4$9&"ZAZ$=F.3\!M  6'Z:,AZ"H+V:APQ(424/334?KC8#PWW39(%\
MI[R,>S=^.S?^NS74%P;HQ/UU=YEE>0.F+)88<);EY/N8SEHIZ?'PR##8O!E"
MF[M*49'1NQ6+DOTMH.]R]:GE=\*'L*8$=!O4-R+5!?8==<OOU$D)E!,?#D3$
M\-(,P]-<%+G/_MAO]<JZ(.SUVH/V@W.Q+"Y]C2P_^&XU'R'QIDEW]&@S]^=W
MJ_/[1,_O2Q@I$BJAW$N94K(S="K?8[Y\K /$BZ,?G[^)?KDXBZ-7K][>C1SR
M;$GHI/OEZV\D'[^H:H+4A70/ :.2],?Q$:*=94$)K8:TCF8G/#_M>+18PJTY
M)838DFFP9GD]1TMH!UA8-QQ^B>J+,_>R\>@-1D1(.?U8)77*Q8&R_&KUP'6^
MK#7FLP"%6*48OF#Z">U [>,_IOK%=0C9&0@T]D6(H2'%D32X+HX2'#W8+?5U
M/LVT=A>5*S97S:4)&PS(\0$_.#NX/'3B.\11_(=7.+NDL_M>/)L73B+<3CM2
MN]LOAQVSVKVW(FJZS%LX,XD3R+M';S) <;E %4+TJ[X[MF]^TPLNFQY:.\O.
M@O&<Y#5FJ:6R*UH3>W97^(8 M(]2"K12W+XR=1@4/>86,;[B@C$I*VVTI5OO
MU/O0J>M3WZ^['H]^.;XXCASJ%%4@^(!HM7E=N "U,\T7B +8NH7,3V=G;^]W
M<?AT8,%3SLFZ(<0F>$^L)G2!),@.9IE73(A879:DAS@\#)^=#XL?Y=L%?XJ+
MO<J2^@@='M9B28I!UTZ[>DK/9Q\7C 9G0(!-P ;) -K5M%+>!>908:A%U;*P
MVYL&5^_PJ9.B(=EW6IU"]G>2_4^[0R,5>3X"_$T;E]C(V7*,&EVB"^;0;M'Y
MCC :5SDVUR#Z(TY0$)PXP7Z# Z(_ -78H"AL%NK3 A=5O[9W;:J[&OIM8&\+
M-8#.D;;"_-2(.&)2P<MRWFMV*B#(+&5EZO/QZY:"$''W7(JA$H9 $Z$6!.%!
MZ X9@CPYIY^&>V :I.T [UMO+6^G]=+7;I1GK+POO13J4Y.F6<ZEYFKI@UUT
M)2"Y@="*<S$62V+25"67.N@SC$*A9\A;8.PU31?6"?1(2\QPE\1<P7458FT%
M"3 &3P3>K"U%<0?PK"@"I)GWT#>?PYU19* JK.F*UUL"#474=?8<SV&YEH:$
M@9I_!::C]KT1D]SATZB1P7HW^= ? 6&1(P$S9&8_#9J?M&O<<O,!M>6R[&?_
MN:;QFD.=,8&:$>%C)7O<D2WN\&%-!P17S69'DZ2@H]1<95D;B T(- 8;+]7^
M\G'#)F@#ZR.']B.'L:GLJ"TK1L^XH45>EGB=5T7.70VI5DT[@M$S!%/+URN&
MGU%I!-Q+ A$DB.ZRQ371/@'=OEQ&+;K<>"PI="Y:<L)F_CZ<(4>J - X\"$4
M&PECXJV/WT,Q];^%'ZIE/940+>9]"0&!C LH;U6I.HO(EI<\>WH4[)V]'[MQ
M]-U$^)&29: *Q4$=I/#P8KC(D"A%P-ZY1Y'A76P-4V38J^\PT&EFD3:Q<"<M
M&A17(?.B&V.B8B@NCKMAL03!\^S1"7(,,N<*%1N.$:LT.,[OL17(<U-V"+UO
M6WN:VU T'H?/X?@FB,>'D7@N+_F0EVF/+(EX1(*(?*R<,P*Z<96P!@(C\Y3O
MH?%,&9%!@,B@*!VDAU&P;JSC-BR<@'Q#5&!PU/'2Q>J#!6B6*;UE(%WDE^B2
MLBN1EDBM>/9\/.$4)BZ[(W5OV=I%Z0)TX!G!,A55>7E$]Q6EB<!XYY_2;-(M
M>/*+!I=P9]7VF) ])N1><:+O]IB0KT,6_B"8D*\U6GKR0,*E9[XP_AE?=4^%
M >OWC9KZ.RU%PB[;)+Z6P*'':.PP;T*O"1D#8@%3".S? !G$.-#"=_3;')N?
M<T-_))*Z2BQ;ZTU+Q&AG1"JA-4#E$Q2*4(>!&<U@*<C1=FYYE@K<HS.=@;DX
MFQTKY_6O.7=;#E R$^&LV,66K*4OE0T)9L=L;MHZ8(C+34P<1S2.594&[6)@
M*;%WUYBN@+K@"N\@@T]:Q0PE4XK3,+^=/U-@GH+Y)6"<+GQ&>^GU[2.!Y(35
MGH/%S(["8!7@9\C3(@@.K1;9]\/HG1Z3R7:OC]W[J=(SF7)].59_YAHYKOC@
MD$F8P6KO= !J1C*#P<#>R9:Q9 X B_99MD^Y-TZB_T;N%.(QIDA+P,UYGRMC
M7X?S29C.DY/CD^B-OY1L:GZ7"$Z,ICH((B9AS#VXOBI=88CDM2KR,XCF=JZ-
M*"Q#,+%TO)5=8Z\.D8\9&86@D:5GI1&$%'5\>80%'PVIPZ<&^6FOL9V!!?#G
M*Q!S9&;6R#C']^"R47VYQ!":Z"B,D353@85((%E!CFTE?$-!) 5^6V?N+J)P
ML=F%, 3B:%5Y=9@FWF3_.!9I@D@K#H@G#4=6.#)%[Y!9/>6KMS0L,L'K\8*5
M+8%E#2A%-'60H14$>\M+$)NEF.5U@W"5V;(1DA#]$WP1>8ZF^2)@*-&EEA_=
MA3A0]Z3$1 .;0,&2'L$-)Z>\U&%;^L%;;!L2.\J FKR=KRF7Q'^7D7H'*7R>
M )7,"K8.5M4?U. 8#\XL=H:18W-M;#!\R#+" \;QH8YH<)<>_R+-6+AE)-'!
MC'.!2U=DUP1>)NVDK,*FT?;&MD&=3%J?\0E&HHF928%HS0^.JX5I4Y"?:))(
M8!I%SYGQ(=4MKX<LCM&"NB*UI^-Q4V<DF%]D,-?@1'#=%'TRZ*5MTX#'W'/"
MD"'VH:K6HHWEITE5+LW.:4C3H;O#_(BNH&Q^UQ0>C_2\M Z &0_U!%ZO4+<U
M_Y&K";Y5,)M"!Y 2KSUP?$;6)^SQ)&/"<["!(BU*+V6T, E(7H9]$?%]C9=3
M>W0OD+KF[?JJQ%V3$YA7\_T\R!B(*BM7>U<U*%-MW&!M@S6+R.:8H>+0?E^A
MB1)W;).H8YJPG=$U'@1_$](B3+*A2QP3>-O>XEW-Z6 ^&]Y#>JU[??=O8@9&
MKK^*H]MO8L)GF&\]5<*6R&7NM<MZ!_S"#5)F"E/1K90JD?Y6]G$56HH-:G8I
MBD?WD1[.MZKYPIKKWU"S\/UO83M#5MH=^]!\>D_U/Z2K>T\$^\EI9[7?.>E^
M?Y77H)J89G,G^N>\[X.XHOK[;SFCR 8-XP$W36,Y&\,HPAOD'V(C3*@CA9,S
M#$*Q'6BB4)L9S-BZ(F@XN3@<5;,?HU^S!>@"0/VG>D]I(S*M,MT;>H^Z93M<
M(E- (>8S[I 3)Z5K^MAQ+?:G<KM3^7 \HJ 37B0HZC_F[*^<"Q[FLU"@,S,P
M<RQ*VTM^NV7H)%GKQ"L"VF$T"?3BL&'A0!#4V+8/8M/"$!03H%;;;\;:'-3W
M!<?GT9OHDY-<@D&&OWL6OG,-);$/W0R $WL4PER:JH"U/H4P6E1;< A':RF$
MD9)U,X>P!W,_Y2*U'H<P0L.B81+A:"L.8=N?MD<B;'4/CM4R9RB+,)H!FVB$
MHUM9A*5,=SV-L,/?K6,1EA3:1AKA:".+,)8'!C3">[3&'JUQGQ<_V:,UO@Y9
MV*,U?M^LVR,D67LF_4M=ENW6ZJ3/@,O8RBSJD@_WK"3'O(JPY*+ =*YKQQ++
MK50VR[D$[H:>U\TC"2]'2* JX43NJSXP-%.O3F9-I/$6[2 #_Y8J)AL2$<9X
M[NW,G-SXB"Y/O&9R>J3RR!U/EA.%!Y1[W8<P48D09%Z!%:9OK5\ 'C(':P+B
M=_V6XZ3W3U9N>HG75K4= 2T5O)K#)/,J=9923._*2V<VY7-/.R>Q'K!)&'5>
M<S$$&';+^:2VG5!74A#3LL<IE.O#O3R&(,)=-A/>,S;NT%G#,PU^,8Z];B^)
MN3/-$'P#KZC!"$'B7Z1!LSUMG <7V,J6*3^H1AR&_IK^!TR^HDU6>)[^">$:
MS$)9W#!S_T0Q<HW<P%=<AHU,70[1V4X 87+@#'-HD@-ZZ<I@<"\/DD8:D"9S
M2T9''1L9E@TO9M@292I(HG$WJ)MP>Q?^A6<@*;"!]RN:Q+%.5D><K>DX.#2:
M*08C2(SI!.;!= =!)?Q(?6(2-K>@XAR?5#I4)AG8$=X##B1X<IU;FR9$M_5,
M&(]L4X&(>PH84!2!XEA7.6YU!UYO)-<T+9(E-31 _\BY)Y2+0\>-%0X5=^@E
M@^-P8M5H?Q&F>.2F$5+E11Z!K0LEL4G6<H+NPQY;ACT>CT=PZS]GC0TV[7^[
MW=A)D.-UU;L6,-R W9-5?M)EUO-2JPER'&CT@P)RH(5C8F8HJ?B'+Y\TMT?,
MU*E,T2F-7=P_CKS>!@=SG>+&FDY1W_A\"@)X1>[1:.PUK]/D&1623*G0IC1%
M,@%'%(ZBS!S"K4/TO/;9VW0YVW!+N$Y<VWZ]VZ@KN&,44R=WC62[@QMWBR(6
M9/;2^,*QMO7=MI@*YT<F3A<!HC(CE<T2<9$GR*W *W+$_/1HI7!+L($GS=#"
M .L2I4-EBQFX8Z.H*8RT2?OV6]4,M7)9IV CUJ]\-3NM^FGJTUJ$/[LT4D@B
MN]>A6^K0;_$H:;+P+9SN^FGTBL4$-"IX5(T-&N^S^)^6Q?_V^ 37$MM8D.;Y
M40K:=IFN-^6BBC#9:;HL,T7*&[MW8(2??%=*3H$3E)E\] )%C-U;CO:W$MV7
M;WDV-^;_%ZR-35 W,1?$7U-3 ;()&Z?;$(1E3%KXPS^72>'\M"8.\E"->N9S
M\E$./KVGY%DPPEY727:9QR-F?89I]DU6[DZ(K2.1TBY+FV$3EA)FTA*%UM[0
MA/HZR5M@1I^(E-MK@7MJ@=.@%Q:J!!>+&8_^@P(TG[&]")_*C6>1VZ.A?4&Y
MZ(&H%.9)IDF-KJ!$=8PG+?6Y;-HVSNERT:SPE'A42MB>A )+%,OQ#G8U8=#'
M,5@:K.B4$HF9%?F$@2O%[X9#]4JZ\DE-3$"Q#H[#/R[.H[-YAA0R?8@;>_A#
MP!<TM#OSB'2*9:6#P>?%/2-)75/N#2M3UVEP:E*A-[&#4$4NB*AQ((M'<O$[
M$PS4X%>'$B1H\GP+J)P^/@0]WVV'B.ZRFUC K5E$S^HRW(Y*5L&SG;T$E0GC
M7BE=1X57S)F_A%Z6T^/MZ:Q>O'S][FQ/A/F)5N=WX]'S?T_FBZ=OHO]:8O-*
M./P)'(??_(KI9YCNGE3B9;YGT[>-35ZQLL3 =$T;-V.4V2]K"PJTC[@Q!1\0
M;F%(Q\% GQ[_F7@CJ$MN+Q8:@,_S^3Q+<\8:VY(5UT@*;*B[6$TO2S ;811=
M>PG+0.]$([)U\^P$BR]@/1,7PWD%$SOZ96$@,ASE55(A0TEY>GSZ'7>>.NP3
M7OZ"=_T-Z!)<553Q1'#,-R*WJ-O8 [OMW-4$,YV +3&'A]P@\-1A-+PD6*=Y
M2@YV!](]P,$>'C@&A-);0%,*DCQRQ*LU]5_..QP7,O"]D[VENGLR'KV"FXM#
M:4]#F^"M@Y'L(FKYE(P^*BXB0\4'Y:92Z;#$N(_'KF!T$2T1],+J22ZG*\8]
MOT8Y4>;XPHT?=470I=@ 88@%"8TQZEL=5*UV.[-C&BTC-G"&5@F-/;(V"J2F
MTZ9X*(+F^V.OZ1;-N0;*R%YGT5"3'CY" 9^+/3([Z[TI;1N:+A2[U\PQVJ.%
M]FBA3WKQ]WNTT-<A"T/[\X4?]/VMWKO5O\?$<Y7B?4"WWN?I".NQT@( %M@.
MW"2*F]9D.E'!1C9_SQ\D ^X2A^HJ63U<5_/X>+?^"@YVD^93!UL)T "QOI=&
M(V%5OL?2*N1HR\FZQE=2.2^_$W[#[@HER8)WY6K*XBBJFQ),Z*M\@?=TD24-
MNR46&2,Q#XFG^W?+W2IHZR#R:Z(.9"!1Z"C)"[RW80;\V56GB:,K,>HU<41C
M@;ECZNU25>/1FGZ'>RMZN_-V^@ ;9X"=A?&QG9\UBLZK-]VS,S'@*2GBO&&R
MTL)[?NQ52P%^KD.,/&<JP^$P7DIX>3U-Y'PY5UU8(]1=]\^AE@YP&1[&&C!;
M+%NI%T*SLR9:3N%Y2>9(TJZ1V&ON[LSETGGSH1G :4T0+'_-Q8WP_12.$,FY
MUA+2E_UH^&ACC::P+N#GF'A5ZJY#+U8++,G:I3>Y+,>FO+HMKJ2Y4A=8?%H)
M.XJ?=UJOOU+$OT1X1*P^Y7IE(83$XXD%4]+?"A_)H67"0"8UO4N?(_D:K<3,
M!3#($54',/#]AW!" 56S:UY/([;I&?!15(,I+4=+RKOA;K)>S800R#5*)#@&
M77MJ'YV\FZ(Y"7O]16>NML;X>B X% />)\7NE10[17:>%SCX&ESW%UF/D^=^
M1NSG3HI3JDK*PA'CDF/EUR)9*4=$R!AA$C"@*F@=U#JR7"=20\Y/H; ?$E33
M"L6<ZBD8.TDEI?FEPHYG61]9SBI6XJS=A(M"68<KO%W;L #F%4S)0(+I<NQ,
MJ8>CZD=KQB,;Z/:W =& ^"I_X0!/A/0>M\'&6[^)+&.OT&PP(ILS5_NCNI.C
M>@JG@64[^CN($H;&\X_1P;>'8-W"<ZZ^*D#+0,3=DF<K(S@6BG(87,\U6G:(
M;+N*HY LQ_=7!SF7RD_$LQ/S1,Q6B3O*>%SM<:;C:Q\22UJ<CF[B?#(V9^B1
M49WDC>'9=,ED<_SSLJTK,#.\9O$6FG+LWUQ5]"CA%=?$ACXU/+-/I3$H/H".
M533/YA.,'SFDMW^V<*@3L@ /,:$0W/)*IQI9:SC<>9&[&'/2--4T-WG[[@MC
M+BX1B6A8$+%_*<AAF)W*2]BBI#!0@8V9;$-*[K9<GK2T21ZJ^*PD\V4[O P_
M>*]^[JM^'D:_<)V0)$UV:RN\-CU-RPS/N[Q%?ZE)3L=<0QPUG1N7^P0$1&SP
M#2NW="K;QLE[YHK%F3=6RI^Y^Y8OB1>*V;T0W5.('O%FC$=G7M_L&'2E^3>&
M=P]EG;JE..J+;K:-3/J>@F1A\EX3Q&"&-KVJ,:0\"^XJJ;]?GSQC,1YZ9?B-
M96GXYGJ\M [837;R5%)?IG'ER9,'1VFRDL9M'80!>-;,TA "O=;K6(DM4&]/
M=[X('Z_729:ZJPD-Z^!@AF=6+A8#;0C-2O3'!WI3K8,CC4?TKL/]";[O"7X,
M_HQ#..ST"C@+D39T!; MU-'RL/>HPEEZ_FD1%>16O3/LA]?XK6799$44J':T
MU1"Q,4%$FOTXGEG^? B+= 0CTC?674<7JP:;46GW[0/I?,6P/=_@ZY"?P&.&
M(X+XE-B!4SA@.%_ CF>1-B/L057VP>HM8TBG<-Q!)^>7V)Z]1D87,%HPH#1E
M<J7=8#U>#_00BC<W<"JW\L+UHG+X,8Q>D'&,>-!JQ:Z*T;!]BO)UF(WM!F";
M@!%X!35_"3?@55+,UK)S#4T87(Y8YJ,Y'?TIIE9Z[&U@'",E</TE$\RL(JER
MN\QGK27DDW!_=&#\A"*[)"0,+!7%?#$B3'H?P?K+IJWF'-.G86_H<'3H[$?]
M5DS-/HL<_Q6L_:4+#NE':9#NP^*<R-U=FR^SF1!@>/!ITU58L)<$U$#^X]%!
M"F\#C3>EUFLLY8>ZY1AH;ZDOIU;N(5X<EIQJ&(@%C21J_5."K4?7]";!2%/.
M[08DZ$[!<%=BCT6U64$)PZO<N6$NWCY00=\3RP-V.<&FP-3$@.:E71$>1O:2
M%X01,CAKX3-"OW].#&V.>FC+*O9ND[$TF4OGQ$56)D6[DGIV;.]XG1>@O>L<
M60>*'B@KQ&M9O!<7"LZ8Y)KE7^1RD2 ,BT=.N<VK)%V?<M"J0WJ:ZV.;ETL/
M->2V?/I(Z8Q5A&$\+KF,37,TVQ>9ABXHR3MTR8HZJ;UH;6:/<NQ,AVG:<L)]
MNFBX%H*#_9RQ:FP39*K/K0K)V]$*I]1&DUL'T\F3LE</S31>HK2<7'O5>HMR
MXT6"LSKY_KOO8L+,"@_!'DNVQY+=#TMV\F /)OLZA&%//?6;&_</V900QB32
MTV]>G#W;#>O$74WZ?SV+'GQ7Z?U;K"R[(W[QE^.+XZA)2FW,FJ1@'VET2ISX
M-VR PK/U9CUCWH=G?*7K8/!9X]%S;.+=6H;0]S5UI%Y%KAH,=]_5L/C6 (9$
M2WFQUCDB:B"LBSF/1Z:+ .'BD%W=D7.&F2-01A_ A;E.P%\A<X:@0>[1LE2-
MZ57U:Y7#_*Z99H0L]Y+]";MK9+IFPO.@J:;%LD8[.**^)%1K)X$]W.)KVYL*
M1L";O^7F19V]&X_L(=M'(&Y14H\H)YNMHE<)B0WNRZOD9G<$P-9.[RB+C28W
M=;2GBG\I[G4HJ2S5SB;<T$1065;/VA)1W]6[QFAA^B'+%LQ<@['71563CK&=
M09R:(0F<"NQ/M4  ^GGG'N"-[ >$+! ;FQ/(%"- \A2WQEBMNFQ%ZF$J%N@J
M6>?!$#&MH$(NM#^?1O%,^(&^'(?!9?#$+I<Y5@J7K""YDT)P@.CL$F2/%.$Z
M!I?H'B0(@_+F]**W*:18VM8DA5XJ#A );IAS=^U0@W*A;6XJ%"'7<4"OK,%1
MXR435C,)U+-IS<TV0*FF=4U[/;6EGGI,!_ FJ=.C5U7U@0+:K@7$KHB\9O*&
M@M]@FDQ%!P9$,,^24G),KN;SN[,!<-395)J N(^=G.O'SK6U$WSH,&Q786V[
M=>B# ?B*7+6FFLR7!A!BA4'H8-;4\RQU8./$AC0F29-30,5T[G!U;F'[>BH5
MF"7PE+T0;RG$WX)Q(LCM;Z)GGG]F-YT%,:GKGXE-VBY+K\6[W7A<OKG/U>/X
M\2G0O:J6PHNV+E]UE3#0(46,7XI%#&%?K\BT]5H-("%Z==$4;>/?SY.6?D5@
M:VV3-=DW?=A6Y+X;C_JEZ_>5MP>_;3KW8GJ5@?AFT4,==]CDIT&1<UE),HJT
M1+W 2'T/C*#E$[&OJR ]O;%,>)@+80!!$7 AW,-.TGV3;CD]&I%^'05%D-.
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M]< E AHE<ZUF7+B>E.V5YW/K+8!KXQ4A%16B'HXCTVL/OHU"5A75I0ML]JQ
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MC:(:9KM)$1U#62E,=/'2,X487]@PY&)I^H:V[HJ*KI:PVVA+@LJYX@W+O/S
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M^^9/6[M[6Z=,]7$_6OK;&^R%4)<I6@*$IV3VAW[>6FI'F0W%P81L/\&P*IT
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M)COL&UO0-",(9B%-4T*]09:K6RC+AMK20Y@\L64F#C=.LF]%N$W(O+^E',)
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MF#>M +6E.LGU3LF9B5Y-16>;50OP0EBB,'_<9(7NQWAD>X^K0QEDI&!:5+N
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M-Q0$<<B*F</9-DMR@!#;@2WM,.CBCY,'P+3<PW0]34&_AL93Y"G"6CJQLB7
MK/93NBA*;_$J.3$F>TNY4?(:Y/O@X8/#KN$PC)ADP#"2AQ&U<<T?4_7@ESXI
M2S!7V3<.VC3BB7F+5&W1PTXCK28ZH$=L0;Y(D579W?'H+4WZ?B2.!\3S/R-6
M:(G7H7Z)G>:B3KO\*_Q?5@ +C4OII\C7%BZZV/V+=<KPI_F1EW52MN:9<51S
MS7*-G=UJ!4/[1Q=9F7:TE\<OH(W4(+X_0O('$P#$U'T8 :2 (S>>3Q9Y2Y&
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M]PXTCZUT=IP-3IN0S.*E_<=4&!@<BZ''2/!LA%;JHR]@;>P9G:'5;Q>5J=.
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MD;;VHR6=<6OK&>?LVC67SZR&=LBO?#8-P>=>[FSXCC!_6DF30L))-\PYPQ*
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MIO!D?D54FBE]"_IF Q2.WK7R"I'J.?6L+1R9LO[5F8K(Z]!'[Y6C>/!B=:Q
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M&5(()"67GK?$F,R?:>R7XL]!_P)02P,$%     @ (8')4K!SNRY@#0  QCP
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MLOKI^9 FU;H1D+IQ4V(<IC'?(^I21 <RGNR22SD0.3D1-^0\'="D',WE_PG
MUAF.8;TO)\>7O2-R<7EXV;O8;^'JKPR#BU[WR_GQY7'O@AR>')'>?[J_'I[\
MTB/=T\^?CR\NCD]/7B5:OQ]>_'I\\LOEZ<D..6IVFQ ]M]W@.Z%R?[C_\=/X
MT-Q[E13_<'K^F:QT7X)YU/-<WQ0B< ,W##M^Z$9<6,*F//39HSQ:%4^H4.#
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M@1:XJ\_9; "/'=%PM]G]> QS+9>]>XOW;H>3X3;E+OD)C/D'VWQ$N^S,!>J
M3&00T]79-NWF4JJI S0#6/6*X['7O]>?787;Y@[!_][MO=!.R;JB=HGG9%"
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M_P)02P$"% ,4    "  A@<E2>/VTGLC3  ![204 #P              @ $
M    8V5L<V-I7V5X,3$N:'1M4$L! A0#%     @ (8')4H@H3F4S P  :A0
M  \              ( !]=,  &-E;'-C:5]E>#(S+FAT;5!+ 0(4 Q0    (
M "&!R5(C'VW.'0<  "4T   .              "  577  !C96QS8VE?97@U
M+FAT;5!+ 0(4 Q0    ( "&!R5*P<[LN8 T  ,8\   0              "
M 9[>  !C96QS8VE?97@Y.3$N:'1M4$L! A0#%     @ (8')4H;0E"+&#0
M>3\  !               ( !+.P  &-E;'-C:5]E>#DY,BYH=&U02P$"% ,4
M    "  A@<E2:4")DU$7  !$E   $               @ $@^@  8W9M+3(P
M,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( "&!R5)@CO'\;@,  ,$+   0
M      "  9\1 0!C=FTM,C R,3$R,S$N>'-D4$L! A0#%     @ (8')4NLC
MY"\U!@  ^#T  !0              ( !.Q4! &-V;2TR,#(Q,3(S,5]L86(N
M>&UL4$L! A0#%     @ (8')4AB9B.UV!   .2T  !0              ( !
MHAL! &-V;2TR,#(Q,3(S,5]P<F4N>&UL4$L%!@     )  D ,@(  $H@ 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
